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ABSTRACT
The human body is formed from the DNA code within a person’s zygote. As the body is
programmatically built from the zygote, the swarms of RNA/DNA greatly increase, eventu-
ally forming the neurological system and kick-starting it to become intelligent. The human
body is gradually but continuously changing; we call this gradual accumulation of changes,
aging. We age at different rates, in different forms, depending on many factors throughout
our lifespan. Ultimately, the many physical systems that make up our body begin to fail at
the same time and in mutually detrimental ways.
The human body is a machine, and like any machine, it can be modeled, predicted, and
maintained for a substantial length of time. We may postpone or reduce the undesired ef-
fects of aging. Maintaining physical and mental health, avoiding disorders, and remaining
active and independent. Aging is part of the human experience, and we can strive to make it
positive. This forms the basis for considering wellbeing in older age, healthy aging. Quanti-
fying the human body as a machine can illuminate what are the elements of a healthy aging
process and avoid undesirable outcomes. We may predict the aging trajectory, the rate and
form of changes, the occurrence of degenerative disorders such as Alzheimer’s, Parkinson’s,
and Amyotrophic lateral sclerosis (ALS). We may prescribe lifestyle changes. We may in-
tervene and prevent an undesirable trajectory.
In pursuit of healthy aging, we utilize data-driven approaches to learn and model the
aging of the human body. We utilize the power of data analytics, machine learning, cloud
computing, and well-curated datasets. We use machine learning techniques on longitudinal
data to develop descriptive, predictive, and prescriptive models of aging. We focus on aging
and neurological disorders as one of the most prominent health disorders in our aging popu-
lation. Our solutions impact the whole spectrum of healthcare from patients and caregivers
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CHAPTER 1: INTRODUCTION
In this thesis, “Learning A Long Healthy Aging”, our mission is to use Machine Learn-
ing to describe, predict, and prescribe a Long-itudinal Healthy Aging. To do so, we take a
multi-disciplinary approach to the problem, which can be described by three principal com-
ponents: (i) healthy aging, (ii) longitudinal and multi-modal data, (iii) machine learning and
cloud computing. In this chapter, we start by providing a background on aging and human
modeling. Then, we outline our approach, strategy, and keystone challenges to overcome.
Finally, at the end of this chapter, we lay out the roadmap of this dissertation.
1.1 BACKGROUND
The human body is formed from the DNA code within a person’s zygote. As the body is
programmatically built from the zygote, the swarms of RNA/DNA greatly increase, eventu-
ally forming the neurological system and kick-starting it to become intelligent. The human
body is gradually but continuously changing; we call this gradual accumulation of changes,
aging. We age at different rates, in different forms, depending on many factors throughout
our lifespan. Ultimately, the many physical systems that make up our body begin to fail at
the same time and in mutually detrimental ways.
The human body is a machine, and like any machine, it can be modeled, predicted, and
maintained for a substantial length of time. We may postpone or reduce the undesired ef-
fects of aging. Maintaining physical and mental health, avoiding disorders, and remaining
active and independent. Aging is part of the human experience, and we can strive to make it
positive. This forms the basis for considering wellbeing in older age, healthy aging. Quanti-
fying the human body as a machine can illuminate what are the elements of a healthy aging
process and avoid undesirable outcomes. We may predict the aging trajectory, the rate and
form of changes, the occurrence of degenerative disorders such as Alzheimer’s, Parkinson’s,
and Amyotrophic lateral sclerosis (ALS). We may prescribe lifestyle changes. We may in-
tervene and prevent an undesirable trajectory.
In pursuit of healthy aging, we utilize data-driven approaches to learn and model the
aging of the human body. We utilize the power of data analytics, machine learning, high-
performance computing, and well-curated datasets. We use machine learning techniques on
longitudinal data to develop descriptive, predictive, and prescriptive models of aging. We
1
focus on aging and neurological disorders as one of the most prominent health disorders in
our aging population. Our solutions impact the whole spectrum of healthcare from patients
and caregivers to physicians and clinicians to providers and insurers.
1.1.1 Health and Aging Human Body
The human body goes through physiological changes leading to senescence, the decline of
biological functions. Calling this process “aging,” it begins as soon as adulthood is reached.
With age, bones shrink in size and density, more susceptible to fracture. Muscles lose
strength, endurance, and flexibility – factors that affect coordination, stability, and balance.
The brain undergoes changes affecting memory or thinking skills, hearing may diminish,
vision may cloud, gums may recede, skin thins and becomes less elastic.
However, we may postpone or reduce the undesired effects of aging. Maintaining physical
and mental health, avoiding disorders, and remaining active and independent. This form of
aging is referred to as “healthy aging” or more formally by the World Health Organization
(WHO) “as the process of developing and maintaining the functional ability that enables
wellbeing in older age” [1].
1.1.2 Human Body as a Machine
For over a thousand years, since the time of ancient Greeks and Aristotle, the idea of élan
vital or “vital force” was endured by many in the West. The idea that living organisms
are fundamentally different from non-living entities because they contain some non-physical
element or are governed by different principles than are inanimate things [2]. Until Leonardo
da Vinci and Andreas Vesalius began dissections and circulated anatomical drawings in the
early 1500s [3]. It became evident that bones and muscles were just systems of levers,
ropes, and pulleys. However, it was not until the early 1600’s that the French philosopher
René Descartes replaced vitalism with scientific materialism. In 1637, Descartes, the great
philosopher, mathematician, and natural scientist, published one of his most important texts,
namely the Discourse on the Method of Rightly Conducting one’s Reason and Seeking the
Truth in the Sciences, commonly known as the Discourse [4]. He proposed the concept of
body as a machine, although a very complicated one [5]. His formulation of the body-soul
problem has served as the starting point for most historical inquiries. The bodies of hu-
mans and brutes according to Descartes were complex machines whose many actions and
physiological functions were caused by the mechanical motions of their parts following “from
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the mere arrangement of the machine’s organs every bit as naturally as the movements of a
clock or other automaton follow from the arrangement of its counter-weights and wheels” [6].
Descartes’s metaphor of body as a machine became increasingly influential as the industrial
revolution transformed society [7]. The idea dominated thinking in biology and medicine.
Today, we call this new scientific approach to medicine, biomedicine, based on an underlying
idea of the body as a machine that has been called ‘the biomedical model’ [8]. Biomedical
models have improved our lives by encouraging a detailed analysis of the body’s mechanisms
at all levels, from the details of anatomy to understanding how hormones like insulin regu-
late chemicals like glucose [9]. We are now going down to lower levels of genes and molecules.
Over the past century, medicine has been modeled by the traditional medical model, one in
which physicians cure biological disease using biomedical mechanistic reasoning [10]. In this
conventional model, paradigmatic diseases are acute infectious diseases, which are generally
curable, and can be understood and treated using biologic rationale: for a bacterial infection,
treat with an antibiotic to halt the germ’s growth or survival, and thus clear the infection.
However, a more comprehensive and personalized medical model is needed to empower a
new era of medicine. The new medical model is enshrined in “precision medicine,” a medical
model that customizes medical decisions, treatments, or practices tailored to the individual
patient [11]. In one illustration of this approach, scientists have developed a genetic risk score
for type 2 diabetes and coronary artery disease [12]. Evidently, a significant number of insulin
resistance variants are highly associated with higher triglycerides, lower HDL cholesterol, and
greater hepatic steatosis, despite reduced adiposity. Using this new model, investigators have
found that the leaner individuals who carried a heavier genetic burden were more likely to
develop type 2 diabetes or coronary artery disease. Thus, new precision medicine models
can help better define patients commonly classified under the broad umbrella of type 2
diabetes and select them for targeted preventive or therapeutic interventions [13]. Unlike
precision medicine-based models, traditional disease-specific models of a patient with type
2 diabetes and heart failure would have the physician manage these biological disturbances
(in glucose homeostasis, in cardiac function) individually while preventing other diseases or
complications.
1.1.3 Human Body Machine and Computing Machine
Arguably, the “Computer Age” started when Alan Turing in 1936 introduced his abstract
‘computing machines’ in his first major publication, ‘On Computable Numbers, with an Ap-
plication to the Entscheidungsproblem’ [14]. Turing presented a theoretical machine, now
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called ‘Turing Machine,’ that could solve any problem that could be described by simple
instructions encoded on a paper tape. Later on, likely influenced by 300-year old Descartes’s
metaphor of the body as a machine, Alan Turing in his 1950 Mind paper ‘Computing Ma-
chinery and Intelligence,’ [15] introduces what is now called ‘The Turing test’ [16]. Turing
had an idea that computers would become so powerful that they would think. He envisaged
a time when artificial intelligence (AI) would be a reality.
Today, when we must deal with problems that are too complicated for our brains, we
resort to mathematical models and computers. Take weather forecasting: to predict tomor-
row’s weather, we need to take into account so many factors, and so many calculations,
that it could take months, if not years, to come up with an answer. But if we write all we
know about weather in a mathematical model, a computer can do those calculations fast
enough to predict the weather for tomorrow in a few hours. Similar mathematical modeling
approach (a.k.a. simulation-based) has been used in medicine as early as 1979 [17] by devel-
oping a whole generation of biomedical simulation models with the aim of predicting what
will happen in the human bodies under a variety of conditions. Generally, simulation-based
modeling describes a physiological body as a combination of differential equations. For in-
stance, using fluid mechanic models for the analysis of cardiovascular function [18]. This
physics-based simulation modeling requires extensive physical and operational knowledge of
a target system in order to be accurate. This required knowledge is scarce even for the
simplest part of our body.
With the rise of “big data” in healthcare, data-driven modeling has become more feasi-
ble. There are various sources of big medical data, such as administrative claim records,
clinical registries, electronic health records, biometric data, patient-reported data, the in-
ternet, medical imaging, biomarker data, genetic data, prospective cohort studies, and large
clinical trials [19]. However, data has not been the only catalyst for the rise of data-driven
methods in medicine. Advances in analytic techniques in computer science, especially in
machine learning, has been a significant contributor [20]. In the last couple of years, break-
throughs started happening in machine learning. Techniques began working much better,
while new techniques have appeared, especially around artificial neural networks, and when
they were applied to some long-standing and important use cases, better results were gained
[21]. These techniques have also shown to have much broader applications, especially in
medicine [22, 23, 24].
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1.1.4 Awareness of Limitations
“All models are wrong, but some are useful,” a point well made by George Box in his often-
cited remark [25, 26]. Furthermore, he reminds us that “the practical question is how wrong
do they have to be to not be useful” [27]. In hindsight, the idea of the body as a machine has
led to many improvements in medicine; however, one should be aware that it forges beliefs
about the body that oversimplify ideas of how the body works and how the disease works
[28, 29]. Because humans are evolved, they are fundamentally different from human-made
machines. Recognizing the limitations, in this work, we will point out model approximations
where the machine fails to recognize evolution and organic complexity. Ultimately, a body
is a body is a body is a body1, but as John von Neumann said: “truth ... is much too
complicated to allow anything but approximations” [30].
1.2 THESIS STATEMENT
Machine learning enables the construction of the human aging model. Descriptive, predic-
tive, prescriptive machine learning methods contribute to this human aging model and permit
health-related decisions for clinicians and individuals.
1.3 DISSERTATION FOUNDATIONS
In this thesis, “Learning A Long Healthy Aging”, our mission is to use Machine Learning
to describe, predict, and prescribe a Long-itudinal Healthy Aging. To do so, we take a multi-
disciplinary approach to the problem, which can be described by three principal components:
(i) healthy aging, (ii) longitudinal and multi-modal data, (iii) machine learning and cloud
computing. Here we describe each component in more detail:
1.3.1 Healthy Aging
The human body goes through physiological changes leading to senescence, the decline of
biological functions. Calling this process “aging,” it begins as soon as adulthood is reached
(Figure 1.1). Aging is part of the human experience, and we can strive to make it positive.
This forms the basis for considering wellbeing in older age, healthy aging.
1Homage to “Rose is a rose is a rose is a rose” by Gertrude Stein as part of the 1913 poem “Sacred
Emily.”
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In this thesis, we focus on brain aging and neurological disorders. This subset of aging-
related diseases is representative of a large portion of aging trajectories. According to a recent
study in the Netherlands, 1 in 2 women and 1 in 3 men set to develop dementia, parkinsonism,
or stroke during their lifetimes [31]. They further show that preventive strategies that delay
disease onset of all three diseases by 1-3 years have the potential to reduce these risks by
20%-50%. This study further highlights how taking proactive healthy lifestyle measures,
and early interventions can significantly lessen the risk of these diseases, regardless of age.
The global costs-of-illness for these diseases is estimated to amount to more than 2% of the
world’s annual gross domestic product (GDP), a figure that is set to rise steeply with the
aging of populations and continuing increases in life-expectancy worldwide [32, 33, 34, 35].
As a result, prioritizing these diseases on the global health agenda is crucial [36].
Figure 1.1: Aging of the human body and the quest for healthy aging trajectories.
1.3.2 Longitudinal and Multi-modal Data
Shown in Figure 1.2, our data-driven strategy starts with the collection and integration
of longitudinal studies with highly dimensional multi-modal datasets. In order to develop
a timely model of aging, we need to incorporate longitudinal studies with time-series data.
This includes both short-term and long-term longitudinal data. Short-term data such as
sensory and monitoring device data has a high frequency of data collection, but with a time
window of hours to days. Long-term data, such as clinical assessments, have a low frequency
of data collection with a time window of six months to two years.
Historically, studies biomedical studies have focused on one type of data, e.g., only genetic
or imaging. However, the human body is remarkably complex, and no single modality can
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capture its manifestation in full. Our approach is to utilize any available modality, including
clinical, biological, imaging, environmental, lifestyle, genomics, and multi-omics. We hope
by integrating all of them, we can have a stronger aging model and a better understanding
of the human body.
Figure 1.2: The data-driven strategy of the thesis. Collection and integration of multi-modal
longitudinal data, use of machine learning and cloud computing solutions, and delivering
public health benefits.
1.3.3 Machine Learning and Cloud Computing
With longitudinal and multi-modal data in hand, the next principal component is to de-
velop the human aging model. We utilize machine learning techniques, including supervised,
unsupervised, and semi-supervised learning, to analyze the data and develop models. His-
torically, descriptive modeling has been applied to health data to identify genotypic and
phenotypic relationships. We are now moving toward predictive analytics, building on the
capabilities of descriptive analytics to forecast future onset, diagnosis, and prognosis using
various models and what-if analyses. In the long term, we will utilize prescriptive analyt-
ics to forecast possible outcomes and allow providers to make proactive decisions. We use
these models to predict the body’s aging trajectory that may guide us manipulate what
would otherwise happen, unhealthy aging. We predict the rate and form of changes, the
occurrence of degenerative disorders such as Alzheimer’s, Parkinson’s, and ALS. Ultimately,
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we may prescribe lifestyle changes. We may intervene and prevent an undesirable trajectory.
Analyzing health data and particularly imaging and genomics data, pose severe computa-
tional challenges. Considering the computational demands across the lifecycle of a dataset
–acquisition, storage, distribution, and analysis– genomics is either on par with or the most
demanding of the big data domains [37]. To address the storage and computational chal-
lenges posed by big health data, we design and use cloud computing-based analytical systems
that have transitioned from shared, centralized architectures to distributed, decentralized ar-
chitectures. We perform large-scale computing and utilize storage resources for open science
data sharing. However, in the cloud environment, the computation time is costly, to reduce
the time and cost, it is essential to implement and use optimized machine learning algorithms
that intelligently reduce the network overhead and I/O waste while utilizing CPU resources.
1.4 DISSERTATION OUTLINE
The contributions of this thesis are organized into chapters according to the studied dis-
order and clinical setting:
• In Chapter 2, we study Parkinson’s disease. Using an unsupervised learning approach,
we identify new subtypes of the disorder based on disease progression. We also provide
an in-depth analysis of these subtypes. Furthermore, we develop predictive models
for early diagnosis, prognosis, and clinical trial stratification. This work previously
appeared as [38, 39, 40, 41, 42, 43, 44, 45, 46, 47].
• In Chapter 3, we present our work on Alzheimer’s disease. Similar to the work on
Parkinson’s disease, we use an unsupervised learning approach to identify new subtypes
of the disorder based on disease progression. We also provide an in-depth analysis
of these subtypes. Furthermore, we develop predictive models for early diagnosis,
prognosis, and stratification. This work previously appeared as [48, 49, 50, 51].
• In Chapter 4, we introduce our work on Amyotrophic lateral sclerosis (ALS) disorder.
Similar to Alzheimer’s and Parkinson’s chapters, we use an unsupervised learning
approach to identify new subtypes. However, unlike Parkinson’s and Alzheimer’s,
which have a long multi-year course, we do not predict progression. Since ALS is a
rapidly progressive disorder, we focus on subtype identification and survival analysis.
We also use semi-supervised learning for enhancing subtype identification. A subset
of this work was published previously as [52, 53, 54].
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• In Chapter 5, we present the work on readmission prediction in the Intensive Care
Unit (ICU). Unlike previous chapters where the health issue has a multi-year course,
in the ICU, data is short-term. Short-term data such as sensory and monitoring device
data has a high frequency of data collection, but with a time window of hours to days.
Due to the data collection frequency, different predictive machine learning methods are
used to encapsulate the time-sensitivity of small fluctuations in the patient’s status.
This work was published previously as [55].
• Finally, we conclude by discussing lessons learned and open challenges in learning a
long healthy aging in Chapter 6.
Some of the work that embodies various topics in computer science related to this thesis,
but not described in the thesis, includes the work on cloud computing reliability [56], big
data, and genomic [37], scalable machine learning [57], privacy-preserving data distribution
[58, 59], and scalable genotyping [60].
1.4.1 Keystone Challenges and Contributions
In this dissertation and in the endeavor of learning the aging model, we have faced two
categories of challenges: engineering and clinical. This work has contributed to tackling
both categories. The models in this work are designed for different scenarios, but share the
following designing principles and address four engineering challenges:
1. Lack of data for supervised learning. In order to develop accurate predictive models
based on supervised learning, we need large and reliable data. In healthcare, such
data is mostly not available; labels come from physicians who themselves have a high
misdiagnosis rate. To overcome this challenge, this work heavily relies on labeling data
using unsupervised and semi-supervised learning techniques.
2. Utilization of short-term and long-term longitudinal data. In order to develop a timely
model of aging, we need to incorporate longitudinal studies with time-series data. In
healthcare, we have both short-term and long-term longitudinal data. Short-term data
such as sensory and monitoring device data has a high frequency of data collection,
but with a time window of hours to days. On the other hand, long-term data such as
clinical assessments have a low frequency of data collection with a time window of six
months to two years. In this work, we utilize both types of longitudinal data.
3. Integration of multi-modal data. Many machine learning techniques focus on one type
of data, e.g., only imaging or audio. However, in healthcare, we look at the human
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body from different modalities, and we hope by integrating all of them, we can have a
better understanding of the issue. Utilizing highly dimensional multi-modal datasets,
including clinical, biological, genetic, and imaging data have been part of this work.
4. Interpretability. Using unsupervised machine learning techniques, we have developed
embedding spaces that have guided us in labeling the subjects. Part of this labeling
relies on our success in interpreting the embedding spaces. In this work, we have put
effort into dissecting the machine learning “black box” to understand the results better
and guide the development of models.
We also address the following clinical challenges:
1. Replication of results with other datasets. Validating findings and replication is an
underpinning of research. Generalizing, the same methods and protocols should be
used on a different group of people, or a different setting, and come up with similar
results. In healthcare, lack of data has made replication more sparse. However, in this
work, when possible, we show that results are valid in external datasets.
2. Developing usable models in both clinical and research settings. Models with higher
accuracy demonstrate a more powerful screening capability in assisting the physicians.
However, accuracy is not enough, and we need to further evaluate the machine learning
models for use in a clinical setting. We need to assess the accuracy along with operating
points corresponding to sensitivity (also called the true positive rate, the recall, or
probability of detection) and specificity (true negative rate) of the algorithm with
respect to the reference standards [61]. It is often claimed that these targeted operating
points can be used for different clinical purposes; for instance, a highly sensitive test is
deemed effective at ruling out a disease when negative, whereas a highly specific test is
effective at ruling in a disease when positive. However, these rules are misleading, as
the diagnostic power of any test is determined by both its sensitivity and its specificity
[62]. The tradeoff between specificity and sensitivity is explored in ROC analysis [63].
In this work, we analyze the usability of all the models for clinical settings, not only
the individual operation points but across a range of values for the ability to predict a
dichotomous outcome.
3. Tangible improvement to physician’s decision making. Feature interpretation, as well
as decision making logic, reliability, and robustness analysis of the machine learning
models, is crucial and imperative for clinical applications. This task is much more
complicated for recent techniques. Many recent efforts are short of explaining the
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decision-making logic and model interpretation in healthcare. In this work, we dive
deeper into our machine learning model in an effort to further interpret the results,
capabilities, and limitations. We investigate the most important factors that the ma-
chine learning model has learned in order to predict and classify an event. We review
the clinical literature for additional verification and a better clinical understanding of
the machine learning model. Finally, we examine the advantages and strengths of the
proposed models.
11
CHAPTER 2: LEARNING PARKINSONISM AND PARKINSON’S
DISEASE
In this chapter, we review the work on Predicting onset, progression, and clinical subtypes
of Parkinson’s disease using machine learning. Using an unsupervised learning approach,
we identify new subtypes of the disorder based on disease progression. We also provide
an in-depth analysis of these subtypes. Furthermore, we develop predictive models for
early diagnosis, prognosis, and clinical trial stratification. This work previously appeared as
[38, 39, 40, 41, 42, 43, 44, 45, 46, 47].
The clinical manifestations of Parkinson’s disease are characterized by heterogeneity in age
at onset, disease duration, rate of progression, and a constellation of motor versus non-motor
features. Due to these variable presentations, counseling of patients about their individual
risks and prognosis is limited. There is an unmet need for predictive tests that facilitate
early detection and characterization of distinct disease subtypes as well as improved, indi-
vidualized predictions of the disease course. The emergence of machine learning to detect
hidden patterns in complex, multi-dimensional datasets provides unparalleled opportunities
to address this critical need.
We used unsupervised and supervised machine learning approaches for subtype identifi-
cation and prediction. We used machine learning methods on comprehensive, longitudinal
clinical data from the Parkinson’s Disease Progression Marker Initiative (PPMI) (n=328
cases) to identify patient subtypes and to predict disease progression. The resulting mod-
els were validated in an independent, clinically well-characterized cohort from the Parkin-
son’s Disease Biomarker Program (PDBP) (n=112 cases). Our analysis distinguished three
distinct disease subtypes with highly predictable progression rates, corresponding to slow,
moderate, and fast disease progressors. We achieved highly accurate projections of disease
progression four years after initial diagnosis with an average Area Under the Curve of 0.93
(95% CI: 0.96 ± 0.01 for PDvec1, 0.87 ± 0.03 for PDvec2, and 0.96 ± 0.02 for PDvec3). We
have demonstrated robust replication of these findings in the independent validation cohort.
These data-driven results enable clinicians to deconstruct the heterogeneity within their
patient cohorts. This knowledge could have immediate implications for clinical trials by im-
proving the detection of significant clinical outcomes that might have been masked by cohort
heterogeneity. We anticipate these machine learning models will improve patient counseling,




Parkinson’s disease (PD) is a complex, age-related neurodegenerative disease that is de-
fined by a combination of core diagnostic features, including bradykinesia, rigidity, tremor,
and postural instability [64, 65]. Substantial phenotypic heterogeneity is well recognized
within the disease, which complicates the design and interpretation of clinical trials and lim-
its counseling of patients about their disease risk and prognosis. The clinical manifestations
of PD vary by age at onset, rate of progression, associated treatment complications, as well
as the occurrence and constellation of motor/nonmotor features.
The phenotypic heterogeneity that exists within the PD population poses a major chal-
lenge for clinical care and clinical trial design. A clinical trial has to be suitably powered to
account for interindividual variability, and as a consequence, they are either large, long, and
expensive, or only powered to see dramatic effects. This problem becomes particularly bur-
densome as we move increasingly toward early-stage trials when therapeutic interventions
are likely to be most effective. The ability to predict and account for even a proportion of
the disease course has the potential to reduce the cost of clinical trials significantly and to
increase the ability of such trials to detect treatment effects.
Attempts thus far at the characterization of disease subtypes have followed a path of
clinical observation based on age at onset or categorization based on the most observable
features [66]. Thus, the disease is often separated into early-onset versus late-onset disease,
slow progressive “benign” versus fast progressing “malignant” subtypes, PD with or with-
out dementia, or based on prominent clinical signs into a tremor-dominant versus a postural
instability with gait disorder subtype [67, 68]. This dichotomous separation, while intu-
itive, does not faithfully represent the clinical features of the disease, which are quantitative,
complex, and interrelated. A more realistic representation of the disease and disease course
requires a transition to a data-driven, multi-dimensional schema that encapsulates the con-
stellation of interrelated features and affords the ability to track (and ultimately predict)
change.
Previous studies used cluster analysis, a data-driven approach, to define two to three clin-
ical Parkinson’s disease subtypes [69, 70, 71]. Depth of phenotypic information, as well as
longitudinal assessments in these studies, was variable and often limited to certain clinical
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features and short-term follow-ups. Moreover, many previous studies were limited by insuf-
ficient methods to capture longitudinal changes over multiple assessment visits. A recent
study used cluster analysis to identify patient subtypes and their corresponding progression
rates [71]. However, this study evaluated clusters according to only two time points, baseline,
and short-term follow-up, that were aggregated into a Global Composite Outcome score. In
return, the subtypes did not capture the fluctuations in the prognosis of subtypes. Finally,
in order to be used in practice, subtyping solutions need to be replicated in a different cohort
and to show the reliability of methods in assigning individual patients to a subtype.
We have previously used multi-modal data to produce a highly accurate disease status
classification and to distinguish PD-mimic syndromes from PD [72]. This effort demon-
strated the utility of data-driven approaches in the dissection of complex traits and has also
led us to the next logical step in disease prediction: augmenting a prediction of whether a
person has or will have PD to include a prediction of the timing and direction of the course
of their disease.
Thus, here, we describe our work on the delineation and prediction of the clinical velocity
of PD. The first stage of this effort requires the creation of a multi-dimensional space that
captures both the features of the disease and the progression rate of these features (i.e.,
velocity). Rather than creating a space based on a priori concepts of differential symptoms,
we used data dimensionality reduction methods on the complex clinical features observed
at 48 months after initial diagnosis to create a meaningful spatial representation of each
patient’s status at this time point. After creating this space, we used unsupervised clus-
tering to determine whether there were clear subtypes of disease within this space. This
effort delineated three distinct clinical subtypes corresponding to three groups of patients
progressing at varying velocities (i.e., slow, moderate, and fast progressors). These subtypes
were validated and independently replicated. Following the successful creation of disease
subtypes within a progression space, we created a baseline predictor that accurately pre-
dicted an individual patient’s clinical group membership four years later. This highlights
the utility of machine learning as ancillary diagnostic tools to identify disease subtypes and
to project individualized progression rates based on model predictions.
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2.2 METHODS
2.2.1 Study design and participants
This study included clinical data from the following cohorts: the Parkinson Progres-
sion Marker Initiative (PPMI, http://www.ppmi-info.org/; n=328 PD cases including 114
(35%) female; 172 controls including 66 (38%) female), and the Parkinson Disease Biomark-
ers Program (PDBP, https://pdbp.ninds.nih.gov/; n=112 PD cases including 53 (47%)
female; 45 controls including 25 (56%) female). PPMI average age of PD cases was 67±9.8
and control 66.2±11.1. PDBP average age of PD cases 65±8.6 and control 63.7±9.1. The
PPMI and PDBP cohorts consist of observational data from comprehensively characterized
PD patients and matched controls. All PD patients fulfilled the UK Brain Bank Criteria.
Control subjects had no clinical signs suggestive of parkinsonism, no evidence of cognitive
impairment, and no first-degree relative diagnosed with PD. Both cohort’s data went through
triage for missing data, 48-month assessment, and comprehensive phenotype collection. Age
and MDS-UPDRS Part III (objective motor symptom examination by a trained neurolo-
gist) distribution of cohorts at baseline were investigated using Kernel Density Estimation
(KDE) to show these independent cohorts are identically distributed and ensure the integrity
of replication and validation.
Each contributing study abided by the ethics guidelines set out by their institutional re-
view boards, and all participants gave informed consent for inclusion in both their initial
cohorts and subsequent studies.
For each cohort, a comprehensive and shared set of longitudinally collected common data
elements were selected for analysis. We used the following data:
i International Parkinson’s disease and Movement Disorder Society Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS) Part I, Part II, and Part III [73]
ii Cranial Nerve Examination
iii Montreal Cognitive Assessment [74]
iv Hopkins Verbal Learning Test [75]
v Semantic Fluency test [76]
vi WAIS-III Letter-Number Sequencing Test [77]
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vii Judgment of Line Orientation Test [78]
viii Symbol Digit Modalities Test [79]
ix SCOPA-AUT [80]
x State-Trait Anxiety Inventory for Adults [81]
xi Geriatric Depression Scale [82]
xii Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease [83]
xiii REM-Sleep Behavior Disorder Screening Questionnaire [84]
xiv Epworth Sleepiness Scale [85]
2.2.2 Procedures and statistical analysis
To accompany this report, and to allow independent replication and extension of our
work, we have made the code publicly available for use by non-profit academic researchers
(https://github.com/ffaghri1/PD-progression-ML). The code is part of the supple-
mental information; it includes the rendered Python Jupyter notebook with full step-by-step
statistical and machine learning analysis. For readability, machine learning parameters have
been described in the Python Jupyter notebook and not in the text of the paper. Figure
2.1 illustrates a summary of our analysis workflow. As a first step, we transformed the
dataset into a mathematically meaningful and naturally interpretable format. To achieve
this objective, we a) normalized and b) vectorized all longitudinal data. Specifically, we first
vectorized by transforming all observations of a particular parameter in a column vector,
then appended all parameters together. We then used the min-max method to normalize
the data. The min-max method is preferred for multi-modal longitudinal datasets compared
to z-score, as it preserves the progression pattern.
To develop an interpretable representation of high modality longitudinal data, we next
used the dimensionality reduction techniques. Dimensionality reduction techniques helped
us to build the “progression space” where we can approximate each patient’s position after
the 48-month period. We used the Non-negative Matrix Factorization (NMF) technique to
achieve this aim [86, 87]. Alternative methods, such as principal component analysis and
independent component analysis, did not perform as well as NMF on longitudinal clinical
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Figure 2.1: Workflow of analysis and model development.
data. This was expected due to the non-negative nature of our clinical tests. This process es-
sentially collapses mathematically related parameters into the same multi-dimensional space;
mapping similar data points close together.
Mathematically, NMF factorizes (deconstructs) the data into two matrices. Given a non-
negative matrix X ∈ Rm×n, a non-negative decomposition of the matrix X is a pair of
non-negative matrices U ∈ Rm×p and V ∈ Rp×n such that X = UV . A large number of
patient parameters are aggregated in a model that represents the underlying progression
concept. In this particular use case of NMF, the matrix U contains the progression space
latent vectors, and the matrix V contains progression stand indicators corresponding to the
latent vectors. Latent variables link observation data in the real world to symbolic data in
the modeled world. By further looking into the matrix with progression space’s latent vec-
tors, we can identify the mapping and, consequently, the implications (symbolic dimensions
of the modeled progression space).
Through our use of NMF, we identify primary progressive symptomatologies of the motor,
cognitive, and sleep-based disturbances. Following this, unsupervised learning via Gaussian
Mixture Models (GMM) [88] allowed the data to naturally self-organize into different groups
relating to velocity of decline across symptomatologies, from non-PD controls representing
normal aging to PD subtypes. GMM is a variant of mixture models, compared to other
methods, the parametrization of a GMM allows it to efficiently capture products of varia-
tions in natural phenomena where the data is assumed generated from an independent and
identically distributed mixture of gaussian (normal) distributions. The assumption of nor-
mal distribution (and therefore the use of GMM) is often used for population-based cohort
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phenomenon [89].
We use the Bayesian Information Criterion (BIC) to select the number of PD clusters
(subtypes) [90]. The BIC method recovers the true number of components in the asymp-
totic regime (i.e., much data is available, and we assume that the data was generated i.i.d.
from a mixture of Gaussian distributions). To replicate the subtype identification, we apply
the GMM model developed in the PPMI data to an independent cohort with varying re-
cruitment strategy and design: the PDBP cohort. We show that identified subtypes in the
PDBP are similar to the ones in the PPMI in terms of progression.
After identifying progression classes using unsupervised learning, we built predictive mod-
els utilizing supervised machine learning via ensemble methods, random forest classifier [91].
In preliminary testing, this approach outperformed other methods, such as support vector
machines (SVM) and simple lasso-regression models. Besides the predictive performance,
we chose random forest (RF) due to the nature of our data and problem: (i) RF is intrin-
sically suited for multi-class problems, while SVM is intrinsically two-class, (ii) RF works
well with a mixture of numerical, categorical, and various scale features, (iii) RF can be
used to rank the importance of variables in a classification problem in a natural way which
helps the interpretation of clinical results, (iv) RF gives us the probability of belonging to a
class, which is very helpful when dealing with individual subject progression prediction. We
develop three predictive models to predict the patient’s progression class after 48 months
based on varying input factors: (a) from baseline factors and (b) from baseline and first-year
factors. We also use a feature extraction method, Recursive Feature Elimination (RFE), in
order to find significant parameters in our models.
We validate the effectiveness of our predictive models in two ways. First, we validate the
algorithm using five-fold cross-validation. We randomly divided the PPMI dataset into five
subsamples, retained a single subsample as the validation data for testing the model, and
the remaining four samples used as training data. We repeated the process five times (the
folds), with each of the subsamples used exactly once as the validation data. The perfor-
mance of the algorithm in each fold was measured by the area under the receiver operating
curve (AUC) generated by plotting sensitivity vs. (1− specificity). The five results from the
folds were averaged to produce a single estimation of performance.
To conclusively validate the algorithm, we also evaluated the performance of the predictive
models (trained on the PPMI measurements) on the independent PDBP cohort. We show
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that the predictive models preserve their high accuracy applied to another dataset.
2.3 RESULTS
Figure 2.2 shows the result of the mathematical projection of PD progression, called
Parkinson’s disease progression space. This space shows the relative progression velocity of
each patient in 48 months (i.e., speed and direction). The level of progression velocity is
broken down into three main dimensions: motor, cognitive, and sleep-related disturbances.
Across these trajectories, the unsupervised learning analysis reveals and classifies patients
into three main subtypes of PD, relating to rates of disease progression: PDvec1, PDvec2,
and PDvec3. This shows that we can now map the primary clinical symptomatology and
disease progression velocity from diagnosis in Parkinson’s.
Figure 2.2: Different views of the Parkinson disease progression space with three corre-
sponding projected dimensions (cognitive, motor, and sleep dimensions). Subtypes of PD
are identified using unsupervised learning (PD vector 1, PD vec 2, and PD vec 3). (a) shows
the view of all three dimensions, (b) view of the motor and cognitive dimensions, (c) view
of cognitive and sleep dimensions, and (d) view of sleep and motor dimensions.
Regarding the interpretation of PD progressions space dimensions, Figure 2.3 shows the
mapping guide for how the PPMI’s high-dimensional space of 140 different clinical parame-
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ters is mapped to the three-dimensional embedding of Parkinson’s disease progression space.
The columns represent the projected three dimensions, i.e., motor, cognitive, and sleep-
related trajectories, and the rows are the PPMI clinical parameters. This figure allows us to
not only observe the conversion but also the heterogeneity of some clinical parameters, for
instance, how some of the Epworth Sleepiness Scale parameters reflect both sleep and cog-
nitive disorders, and some reflect both sleep and movement disorders. In comparisons of the
eigenvalues within the NMF decomposition, the projected motor dimension was responsible
for 41.6% of the explained variance, followed by the sleep dimension (29.5%), and cognitive
dimension (28.9%).
Figure 2.3: Shows how each 140 different input parameters have been projected into the new
dimension of the Parkinson’s progression space (cognitive, motor, and sleep dimensions).
Darker colors represent strong mapping.
Regarding the number of identified PD subtypes, Figure 2.4 shows the characteristics of
PDs identified subtypes in more detail. Specifically, Figure 2.4 shows the visualization of un-
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supervised learning via GMM. GMM fits the data into different subtypes relating to velocity
of decline across symptomatologies, from non-PD controls. The BIC method has identified
three Gaussian distributions representing three PD subtypes.
In terms of characteristics of PDs identified subtypes, Figure 2.5 demonstrated how cog-
nitive, motor and sleep-related symptoms differ within each PDs subtype and in controls.
There is a clear trend for increased sleep and motor disturbances after four years in fast pro-
gressors compared to the slower progressing subtypes, which seem to have relatively more
cognitive issues early on.
Figure 2.6 shows the progression of each PD subtype overtime at baseline and after 18
months, 24, 36, and 48 months. To better understand the clinical presentation of the three
identified subtypes, Figure 2.6 demonstrates the three main projected dimensions (motor,
cognitive and sleep-related disturbances), as well as actual clinical values of each subtype
overtime for UPDRS-Part I, Part II, Part III, as well as Hopkins Verbal Learning Test,
Symbol Digit Modalities Test, Semantic Fluency test, Epworth Sleepiness Scale, State-Trait
Anxiety Inventory for Adults, and Geriatric Depression Scale.
In terms of the genetic association of PDs identified subtypes, Genetic Risk Scores (GRS)
were calculated as per [46]. While the GRS was not selected during feature extraction in
the clustering exercise we did analyze regressions comparing associations between the GRS
and either the continuous predicted cluster membership probability (linear regression) or
the binary membership in a particular cluster group compared to the others. All models
were adjusted for age at onset, female gender, and principal components as covariates to
adjust for population substructure in PPMI. The GRS was significantly associated with de-
creasing magnitude of the sleep vector per Standard deviation of increase in the GRS (beta
= -0.0298546, se = 0.0097124, p = 0.00232, adjusted r2 = 0.04584). For binary models of
membership, we see that the GRS is weakly but significantly associated with a decreased
risk of membership in PDvec3 (odds ratio = 0.5630876 per 1 SD increase from case GRS
mean, beta = -0.574320, se = 0.243974, P = 0.01857) and increased risk of membership in
PDvec1 (odds ratio = 1.340952, beta = 0.29338, se = 0.13367, P = 0.028178). The lack of
a strong genetic association is due to the small sample size.
In order to ensure the generalizability and validity of the results, we replicate the subtype
identification in the independent PDBP cohort. Figure 2.7 shows PPMI and PDBP cohorts
are similarly distributed; hence, they are suitable for replication and validation. Further-
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Figure 2.4: Visualization of unsupervised learning via GMM and identification of three
Gaussian distributions representing three distinct PD subtypes. Motor dimension reflects
the increase in disturbance, while the cognitive dimension reflects the decline.
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Figure 2.5: Shows the distribution of projected dimensions (cognitive, motor, and sleep) for
each Parkinson’s category and healthy control after three years. Motor and sleep dimensions
reflect the increase in disturbance, while the cognitive dimension reflects the decline. PDvec3
has the highest motor and sleep disturbance, as well as the highest cognitive decline.
more, we have performed the two-sample t-test for quantified replication cohort validation
analysis (Table 2.1).
Figure 2.8 shows the identified subtypes in the independent PDBP cohort using the model
developed on the PPMI dataset. We see that the identified subtypes in the PDBP are sim-
ilar to the ones in the PPMI in terms of progression. The PPMI and PDPB cohorts are
clinically different cohorts and recruited from different populations. The replication of our
results in the PDBP cohort that was recruited with a different protocol shows the strength
of our study’s methodology. We demonstrate that if we ascertain the same phenotypes using
standardized scales, we can reliably discern the same subtypes and progression rates. This
makes our results generalizable and the clinical subtypes reproducible.
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Figure 2.6: Shows the progression of each PD subtype over time. The top three graphs
show the increased values of motor, sleep, and cognitive dimensions reflect the increase in
disturbance overtime. The rest of the graphs demonstrate the actual clinical values of each
subtype overtime for UPDRS-Part I, Part II, Part III, as well as Hopkins Verbal Learning
Test, Symbol Digit Modalities Test, Semantic Fluency test, Epworth Sleepiness Scale, State-
Trait Anxiety Inventory for Adults, and Geriatric Depression Scale. BL: Baseline. V03: visit
number 3 after 18 months. V04: visit number 4 after 24 months. V06: visit number 6 after
36 months. V08: visit number 8 after 48 months.
24
Figure 2.7: Kernel Density Estimation (KDE) analysis of Age and MDS-UPDRS Part III
(objective motor symptom examination by a trained neurologist) in PPMI and PDBP co-
horts. (a) shows the density of Parkinson’s participant’s age in the 3-years PPMI, PDBP,
and 3-years PDBP datasets, and (b) shows the distribution of Parkinson’s participant’s
MDS-UPDRS Part III at baseline in the 3-years PPMI, PDBP, and 3-years PDBP datasets.
The three density functions in both figures are similar showing the validity of statistical
replication.
Table 2.1: two-sample t-test for quantified replication cohort validation analysis. PPMI vs.
PDBP (selected participants with 3 years data).
Parkinson participant’s distribution of cohorts t-value p-value
Age 0.9244736 0.3557441
UPDRS Part III -1.162273103 0.245751729
Following the data-driven organization of subjects into progression subtypes and cluster-
ing them into three subtypes, we developed three models to predict patient progression class
after 48 months based on varying input factors: (a) from baseline factors, and (b) from
baseline and year 1 factors. Figure 2.9a and Figure 2.9b show the ROC (Receiver Operating
Characteristic) curves of our multi-class supervised learning predictors. We correctly distin-
guish patients with Parkinson’s disease based on baseline only input factors and predict their
48-month prognosis with an average AUC of 0.93 (95% CI: 0.96 ± 0.01 for PDvec1, 0.87 ±
0.03 for PDvec2, and 0.96 ± 0.02 for PDvec3). The predictor built on baseline and year 1
data performs even better with an average AUC of 0.956 (95% CI: 0.99 ± 0.01 for PDvec1,
0.91 ± 0.03 for PDvec2, and 0.97 ± 0.02 for PDvec3). The increased accuracy is due to
the availability of more information about a subject. This approach is also practical in a
clinical setting, as physicians will provide a better prognosis of patients after a year follow up.
The predictive model was also analyzed and enhanced by using a feature extraction
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Figure 2.8: Shows the identified subtypes in the independent PDBP cohort using the model
developed on the PPMI dataset. Similar PDBP and PPMI subtypes in terms of progression.
(a) shows the view of all three dimensions, (b) view of the motor and cognitive dimensions,
(c) view of cognitive and sleep dimensions, and (d) view of sleep and motor dimensions.
method: Recursive Feature Elimination. For the predictive model based only on baseline
factors, out of 140 clinical parameters, 52 were identified to be the significant contributors
(Table 2.2 for list and detail). Essentially, having only 52 parameters will provide us with
the highest prediction accuracy. For the predictive model on baseline and year 1 factors,
incorporating 66 parameters out of 250 (not all factors were measured at both baseline and
first-year) provided us with the highest prediction accuracy (Table 2.2 for list and detail).
From these 66 parameters, 34 are baseline measurements and the same as baseline predictor,
three new baseline measurements, and 29 measurements from the first year.
Besides the cross-validation of predictive models in the PPMI cohort, we have also vali-
dated the accuracy of the predictive model in the independent PDBP cohort. The predictive
model trained on the PPMI baseline data correctly distinguished PDBP patients with AUC
of 0.787 (ROC curves in Figure 2.9c). The replicated predictive model performs very well
for PDvec1 and PDvec3 (AUC of 0.90 and 0.89, respectively). However, due to the small
sample size, the predictive model does not predict as well on PDvec2 (AUC of 0.57). There
are fewer samples that make up the PDvec2 cluster in the replication cohort, and it has been
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Figure 2.9: Shows the performance of Parkinson’s disease progression prediction models.
(a) The ROC for the predictive model at baseline developed on the PPMI cohort evaluated
using five-fold cross-validation. (b) The ROC for the predictive model developed on the
baseline and first-year data of the PPMI cohort evaluated using five-fold cross-validation.
(c) The ROC for the predictive model developed on the PPMI baseline and tested on the
PDBP cohort.
more accessible for the predictive model to predict the more extreme subtypes (i.e., PDvec1
and PDvec3). Despite the smaller sample size of the PDBP cohort, the results strongly
validate our previous observations of distinct, computationally discernible subtypes within
the PD population. This finding indicates that our methodology is robust, and our unique
progression analysis and clustering approach is resulting in the same clusters.
Table 2.2: Summary of clinical parameters with significant contributions to the prediction models.
Table lists significantly contributing clinical parameters based on baseline examination tests (BL) or
based on the baseline with year-1 (BL + Y1) test items. Abbreviations: EPS, Epworth Sleepiness
Scale; HVLT, Hopkins Verbal Learning Test; LNS, Letter-Number Sequencing; MDS-UPDRS,
Movement Disorder Society Revision of the Unified Parkinson’s Disease Rating Scale; MoCA,
Montreal Cognitive Assessment; RBDSQ, REM Sleep Behavior Disorder Screening Questionnaire;
QUIP, Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease; SCOPA-AUT,
Assessment of Autonomic Dysfunction; STAI, State-Trait Anxiety Inventory.
Begin of Table 2.2
Clinical Scale Model
Specific Test Item(s) (Parameter Name) Baseline Baseline
+ Year 1
MDS-UPDRS Part I
1.3 Depressed mood (NP1DPRS) + + (BL)
1.4 Anxious mood (NP1ANXS) + + (BL)
1.7 Sleep problems (NP1SLP) + + (Y1)




Specific Test Item(s) (Parameter Name) Baseline Baseline
+ Year 1
1.11 Constipation problems (NP1CNST) + + (Y1)
1.13 Fatigue (NP1FATG) - + (Y1)
MDS-UPDRS Part II
2.2 Saliva and drooling (NP2SALV) - + (Y1)
2.4 Eating tasks (NP2EAT) + + (Y1)
2.5 Dressing (NP2DRES) + + (BL, Y1)
2.6 Hygiene (NP2HYGN) + -
2.7 Handwriting (NP2HWRT) + + (BL, Y1)
2.8 Doing hobbies and other activities (NP2HOBB) - + (Y1)
2.11 Getting out of bed, car, deep chair (NP2RISE) + + (Y1)
MDS-UPDRS Part III
3.1 Speech (NP3SPCH) + + (BL, Y1)
3.2 Facial expression (NP3FACXP) + + (BL, Y1)
3.3a Rigidity neck (NP3RIGN) + + (Y1)
3.3b Rigidity RUE (NP3RIGRU) + + (BL, Y1)
3.3d Rigidity RLE (NP3RIGRL) - + (Y1)
3.3e Rigidity LLE (NP3RIGLL) + -
3.4a Finger tapping right hand (NP3FTAPR) + + (BL)
3.5b Hand movements left hand (NP3HMOVL) + + (Y1)
3.6a Pronation-supination right hand (NP3PRSPR) + + (BL)
3.6b Pronation-supination left hand (NP3PRSPL) + + (Y1)
3.7b Toe tapping left foot (NP3TTAPL) - + (Y1)
3.8a Leg agility right leg (NP3LGAGR) + + (BL)
3.8b Leg agility left leg (NP3LGAGL) + + (BL, Y1)
3.9 Arising from chair (NP3RISNG) + + (BL)
3.13 Posture (NP3POSTR) + -
3.14 Global Spontaneity of movement (NP3BRADY) + + (Y1)
3.16b Kinetic tremor left hand (NP3KTRML) + + (BL, Y1)
3.17c Rest tremor amplitude RLE (NP3RTARL) - + (Y1)
3.17d Rest tremor amplitude LLE (NP3RTALL) - + (Y1)
3.21 Hoehn and Yahr stage (NHY) + + (BL)
MoCA




Specific Test Item(s) (Parameter Name) Baseline Baseline
+ Year 1
Language total score (Language) - + (BL)
Delayed recall total score (Delayed recall) + + (BL)
Abstraction (MCAABSTR) + + (BL)
MoCA total score (MCATOT) + + (BL)
HVLT
Immediate Recall Trial 1 (HVLTRT1) + + (BL)
Immediate Recall Trial 3 (HVLTRT3) + + (BL)
Delayed Recall (HVLTRDLY) + + (BL)
Recognition (HVLTREC) + + (BL)
Recognition false positives, related (HVLTFPRL) + + (BL)
LNS
LNS-Sum questions 1-7 (LNS TOTRAW) + + (BL)
QUIP
Think having issue with sex behavior (TMSEX) + + (BL)
Think having issue with eating behavior (TMEAT) + + (BL)
RBDSQ
Dreams frequently have aggressive or action-packed content (DR-
MAGRAC)
+ + (BL)
Know my arms and legs move when asleep (SLPLMBMV) + + (Y1)
I (almost) hurt my bed partner or myself (DLPINJUR) + -
In my dreams: speaking, shouting, swearing (DRMVERBL) + + (BL, Y1)
In my dreams: gestures, complex movements useless during sleep
(DRMUMV)
+ -
In my dreams: things fell down around the bed (DRMOBJFL) + + (Y1)
It happens that my movements awake me (MVAWAKEN) - + (BL)
My sleep is frequently disturbed (SLPDSTRB) + + (BL)
Disease of nervous system: stroke (STROKE) + + (BL)
Disease of nervous system: depression (DEPR) + + (BL, Y1)
EPS





Specific Test Item(s) (Parameter Name) Baseline Baseline
+ Year 1
Had difficulty swallowing or have choked + Has saliva dribbled out
of your mouth + Has food become stuck in your throat (Gastrointesti-
nal upper)
+ + (Y1)
Have feeling during meal that you were full very quickly + Had
problems with constipation + Had to strain hard to press stools + Had
involuntary loss of stools (Gastrointestinal lower)
+ + (BL)
Semantic Fluency
Total number of animals (VLTANIM) + + (BL)
Total number of vegetables (VLTVEG) + + (BL)
STAI
Anxiety state score (A state) + + (Y1)
End of Table 2.2
In summary, we have mined data to identify three clinically-related constellations of
symptoms naturally occurring within our longitudinal data that summarize PD progres-
sion (41.6%, 29.5%, 28.9% variance loadings) comprised of factors relating to motor, sleep
and cognitive. We also utilized supervised learning methods to identify the most informa-
tive factors across these symptomatologies to predict the velocities of decline for each patient
relative to matched healthy controls with excellent accuracy (>90% after cross-validation)
from baseline clinical data.
2.4 DISCUSSION
Prediction of disease and disease course is a critical challenge in the care, treatment, and
research of complex heterogeneous diseases. Within PD, meeting this challenge would allow
appropriate planning for patients and symptom-specific care (for example, to mitigate the
chance of falls, identifying patients at high risk for cognitive decline or rapid progression,
etc.). Perhaps even more importantly, at this time, prediction tools would facilitate more
efficient execution of clinical trials. With models predicting a patient-specific disease course,
clinical trials could be shorter, smaller, and would be more likely to detect smaller effects;
thus, decreasing the cost of phase 3 trials dramatically and essentially reducing the exposure
of pharmaceutical companies in a typically expensive and failure-prone area.
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We previously had considerable success in constructing, validating, and replicating a model
that allows a data-driven diagnosis of PD and the differentiation of PD-mimic disorders, such
as those patients who have parkinsonism without evidence of dopaminergic dysfunction [72].
We set out to expand this work by attempting to use a somewhat similar approach to 1)
define natural subtypes of disease; 2) attempt to predict these subtypes at baseline; and 3)
to identify progression rates within each subtype and project progression velocity.
While the work here represents a step forward in our efforts to sub-categorize and predict
PD, much more needs to be done. The application of data-driven efforts to complex prob-
lems such as this clearly works; however, the primary limitation of such approaches is that
they require large datasets to facilitate model construction, validation, and replication. To
achieve the most powerful predictions, these datasets should include standardized pheno-
type collection and recording. Collecting such data is a challenge in PD, with relatively few
cohorts available with deep, wide, well-curated data. Thus, a critical need is the expansion
or replication of efforts such as PPMI or PDBP, importantly with a model that allows un-
fettered access to the associated data; the cost associated with this type of data collection
is large, but these are an essential resource in our efforts in PD research.
2.5 SUMMARY
In this study, we addressed the complexities of Parkinson’s disease. We integrated unla-
beled, multi-modal, and longitudinal data. The longitudinal data had a long-term nature,
and we were interested in capturing the overall pattern of the individual’s trajectories. Vec-
torization and NMF methods were the most successful approach for extracting long-term
trajectories. Using comprehensive multi-modal data helped us develop an embedded space.
This space was crucial for understanding the trajectories and dimensions in which the individ-
uals traverse. Having this easily interpretable space, we were able to use GMM unsupervised
learning approach to identify new subtypes of the disorder based on disease progression. We
also provided an in-depth analysis of these subtypes. Furthermore, we developed predictive
models for early diagnosis, prognosis, and clinical trial stratification.
This work provides data-driven subtypes in distinct progression stages of PD and discusses
an approach to predict the future rate of progression years from baseline using longitudinal
clinical data. Predicting disease progression serves as a paramount challenge in the ther-
apy and cure of several elaborate diseases. This study is a step forward towards designing
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sophisticated machine-learning paradigms to facilitate early diagnosis of PD progression.
Predicting PD progression rates would lead to better patient-specific attention by recogniz-
ing at an early stage the patients with a swift rate of progression. The proposed disease
progression and trajectory prediction algorithms can help doctors and practitioners develop
a methodical and organized course for clinical tests, which can be much more concise and
effective in detection. These adaptations and modifications in clinics may help to diminish
treatment and therapy costs for PD. Further, the capability to anticipate the trajectory of
impending PD progression at the early stages of the disease is an advancement towards un-
covering novel treatments for PD modification. The proposed analysis provides insights to
inhibit or decelerate the progression of PD-related symptoms and subsequent deterioration
in the characteristics of life that are accompanied by the disease.
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CHAPTER 3: LEARNING DEMENTIA AND ALZHEIMER’S DISEASE
In this chapter, we review the work on Predicting Alzheimer’s disease progression tra-
jectory and clinical subtypes using machine learning1. Similar to the work on Parkinson’s
disease, we use an unsupervised learning approach to identify new subtypes of the disor-
der based on disease progression. We also provide an in-depth analysis of these subtypes.
Furthermore, we develop predictive models for early diagnosis, prognosis, and stratification.
This work previously appeared as [48, 49, 50, 51].
Alzheimer’s disease (AD) is a common, age-related, neurodegenerative disease that impairs
a person’s ability to perform day to day activities. Diagnosing AD is difficult, especially in
the early stages, many individuals go undiagnosed partly due to the complex heterogeneity
in disease progression. This highlights a need for early prediction of the disease course to
assist its treatment and tailor therapy options to the disease progression rate. Recent de-
velopments in machine learning techniques provide the potential to not only predict disease
progression and trajectory of AD but also to classify the disease into different etiological
subtypes.
The suggested work clusters participants in distinct and multifaceted progression sub-
groups of AD and discusses an approach to predict the progression stage from baseline
diagnosis. We observe that the myriad of clinically reported symptoms summarized in the
proposed AD progression space corresponds directly to memory and cognitive measures, clas-
sically been used to monitor disease onset and progression. The proposed work concludes
notably accurate prediction of disease progression after four years from the first 12 months
of post-diagnosis clinical data (Area Under the Curve of 0.92 (95% confidence interval (CI),
0.90-0.94), 0.96 (95% CI, 0.92-1.0), 0.90 (95% CI, 0.86-0.94) and 0.83 (95% CI, 0.77-0.89)
for controls, high, moderate and low progression rate patients respectively). Further, we
explore the long short-term memory (LSTM) neural networks to predict the trajectory of a
patient’s progression.
The machine learning techniques presented in this study may assist providers with iden-
tifying different progression rates and trajectories in the early stages of disease progression,
hence allowing for more efficient and unique care deliveries. With additional information
about the progression rate of AD at hand, providers may further individualize the treatment
1This research was assisted by Vipul Satone and Rachneet Kaur as documented in their thesis.
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plans. The predictive tests discussed in this study not only allow for early AD diagnosis
but also facilitate the characterization of distinct AD subtypes relating to trajectories of
disease progression. These findings are a crucial step forward to early disease detection.
Additionally, models can be used to design improved clinical trials for AD research.
3.1 INTRODUCTION
Alzheimer’s disease (AD) is a progressive and age-associated chronic neurodegenerative
disease affecting a patient’s memory, intellectual skills, and other mental functions. It is the
most common form of dementia. Research has shown that AD is a clinically heterogeneous
condition, showing marked variations in terms of the symptoms constellations and disease
progression rates. The clinical signs and symptoms of AD show marked variability in terms
of patients’ age, disease span, progression velocity, and types of memory, cognition, and
depression-related features. After the age of 65, the prevalence of dementia doubles every
five years and is known to increase exponentially after the age of 90 [92]. As dementia affects
older people, with a growing life expectancy, it is becoming a crucial medical problem [93].
With no preventive interventions known, AD progression is a major concern for health
care providers around the globe. Researchers have shown that AD pathological changes
occur 20 years or earlier before the actual disease symptoms manifest [94, 95, 96, 97, 98, 99].
In the absence of any cure or disease-modifying treatment for this disabling disease, current
treatment strategies are limited to supportive, symptomatic care [100, 101]. Delay in the di-
agnosis of AD is often due to the disease complexity, with no clear identifying early diagnostic
criteria available for providers [102]. A major challenge for AD prediction is the presence of
inherent phenotypic diversity in the AD population. Hence, the idea of personalized clinical
care with individualized risk, progression, and prediction related patient advice in AD is
narrow. Additionally, there are ramifications in clinical trial design when considering the
high heterogeneity of disease manifestation and progression. Predicting disease progression
trajectories at an early stage is crucial for the design of clinical trials and the development
of disease-modifying treatment strategies.
For the treatments to be most effective, the AD therapy regimen must likely begin before
the notable downstream damage [103]. Simply put, early AD detection is a likely scenario
to make the greatest therapeutic gains. Patients diagnosed with mild cognitive impairment
(MCI) at study baseline are at a higher risk for progression to dementia, but not all patients
end up developing AD [104]. Research has been done to detect AD in patients with MCI
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or predict the early stage of AD using cerebrospinal fluid (CSF) [105, 106], while others
[107] have used psychometric and imaging data for predicting the progression of dementia
in patients with amnestic MCI. In an implementation of a multi-class classifier using clinical
and magnetic resonance (MR) brain images to classify controls, MCI, and AD patients,
an accuracy of 79.8% was achieved [108]. Less research has been done on using clinical
data and predicting the AD progression rate. Recently, we have used machine learning
to classify Parkinson’s disease (PD) patients into three different sub-categories with highly
predictable progression rates [43]. We explored variations in onset and progression velocity
and observed clusters of the motor, cognitive, and sleep disturbance related features using
the clinical data. In this work, we extend our latest approach by applying it to the clinical
features of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset [109].
3.1.1 Goals and Contributions
This work was designed to cluster AD patients into distinct progression groups and to
predict the progression trajectory at an early baseline period. Dimensionality reduction via
non-negative matrix factorization (NMF) was used to define an ADNI progression space for
the AD summarizing myriad clinical measures across multiple time points. By applying un-
supervised machine learning, namely, the Gaussian mixture model (GMM) on the extensive
clinical observations available in the ADNI dataset, we algorithmically parsed the progres-
sion space for the AD into three clinical subtypes, defined as low, moderate (medium) and
high disease progressors. Our analysis found that clinically related symptoms corresponding
to memory and cognition make up the AD progression space. Clinical data collected at base-
line (study entry), after 6 and 12 months, is used to predict memory and sleep decline after
24 and 48 months from baseline. We validated our models through five-fold cross-validation
to obtain a robust prediction of memberships into these progression subtypes. Along with
traditional machine learning methods, the long short-term memory (LSTM) neural networks
were also used to predict disease progression rates (control, low, moderate, and high) after
24 and 48 months from baseline. The described methodologies may lead a step forward
towards the development of personalized clinical care and counseling for patients, hopefully
reducing AD therapy costs in the future. Also, we attempt to describe the trajectory of AD
progression via LSTM networks.
Further, we examine the reversion instances of AD captured in the constructed progression
space, the correlation of Apolipoprotein Eε4 (APOEε4) compound genotype with cognitive
performance and interactions between certain selective features associated with AD and the
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constructed progression space later in the discussion section of the paper. These observations
provide a promising understanding of AD characteristics useful for devising novel disease
modification therapies. The proposed analysis provides a potential understanding towards
restraining AD-related symptoms and consequent deterioration in the life of the patients. We
believe that the advancement of the discussed prediction models has the potential to impact
clinical decision making and improve healthcare resource allocation in AD significantly.
3.2 METHODS
The data analysis pipeline for this work was performed in Python 3.6 with the support of
several open-source libraries (TensorFlow, scikit-learn, pandas, seaborn, etc.). To facilitate
replication and expansion of this study, the Python code (including the entire data prepro-
cessing and machine learning analysis) was made publicly available under GPLv3 as part of
the supplementary information at https://github.com/vipul105/Alzheimers_Disease_
Progression.
3.2.1 Study design and participants
Data used in the preparation of this article were obtained from the ADNI database
(adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership,
led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been
to test whether serial magnetic resonance imaging (MRI), positron emission tomography
(PET), other biological markers, and clinical and neuropsychological assessments can be
combined to measure the progression of MCI and early AD. The ADNI dataset involves
participants from over 50 sites across North America and Canada. All participants and
their study partners provided their consent, accepting their engagement for the data collec-
tion, and the study protocols for ADNI were approved by the Institutional Review Board.
The ADNI study was carried out in phases, namely, ADNI 1 beginning in 2004, followed
by ADNI GO in 2009 and ADNI 2 in 2011. These editions had different participants and
data collection procedures, accounting for advancement in technologies. For more up-to-date
information, see www.adni-info.org.
The eligibility criteria for the ADNI participants and further details on the protocol can
be found at [109]. All participants went through comprehensive functional, cognitive, and
clinical assessments and provided a blood sample for APOE genotyping at their baseline
visit (study entry). These assessments and their status (control, MCI, and AD) were then
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updated longitudinally at 6, 12, 18, 24, 36, and 48 months. In our analysis, predictions were
made for each participant’s AD stage after 24 and 48 months using up to 12 months of clinical
data. The study consisted of 247 observations (with 123 (49.79%) females, the average age
for all participants was 71.55± 6.79 years and 94.73% of them are of European ancestry) for
prediction at the 48th month and 453 observations (with 208 (45.92%) females, the average
age for all participants is 72.32± 7.13 years, and 93.59% of them are of European ancestry)
for prediction at the 24th month. For observations corresponding to the 24th month, mean
age is 72.84 ± 6.09, 71.61 ± 7.47 and 72.92 ± 8.11 for controls, MCI and dementia patients
respectively and for observations corresponding to the 48th month, the mean age is 72.17 ±
6.67, 71.36 ± 6.67 and 70.34 ± 7.42 for controls, MCI and dementia patients respectively.
The total scores and subscores from the following commonly collected cognitive, functional,
and longitudinal clinical data elements were used in the proposed work:
i Montreal Cognitive Assessment [74]
ii Clinical dementia rating [110]
iii Neuropsychiatric inventory questionnaire [111]
iv Neuropsychological battery [112]
v Mini-mental state exam (MMSE) [113]
vi Geriatric Depression Scale [82]
vii Everyday cognition - study partner [114]
viii Everyday cognition - participant [115]
ix Functional assessment questionnaire (FAQ) [116]
We considered a total of 145 clinical variables (features) from the above-mentioned assess-
ments for our analysis.
3.2.2 Procedures and statistical analysis
Only the observations which had data recorded for all the considered tests were taken into
account. To construct the AD progression space, we used readings taken at baseline and on
visits after 6 and 12 months from the baseline.
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3.2.3 ADNI progression space and the prediction model
We leverage the temporal information present in the data to manage missing data record-
ings. Missing values were imputed using linear interpolation based on the past visit readings
for the feature, therefore avoiding any influence of other observations during data imputa-
tions. After the imputation, around 7% of the data was reduced. One hot encoding was
used for categorical variables whenever required. Scaling the continuous features to a com-
parable range is necessary to avoid the influence of certain features over others. Min-max
normalization was used to retain the progressions since the ADNI dataset in consideration is
multi-modal. Furthermore, min-max normalization didn’t affect categorical features. Figure
3.1 shows our detailed workflow pipeline followed during the analysis. To reduce the dimen-
sionality of the dataset, NMF [86, 87] (with a rank of 2) was used on 582 observations with
available data for baseline, visits after 6 and 12 months. We used NMF to deconstruct data
into two matrices, namely progression vectors and the progression indicators, which corre-
spond to the latent vectors. Progression vectors were used to construct the 2-dimensional
(2D) ADNI progression space. This 2D space was then used to predict a participant’s dis-
ease progression stage after 24 and 48 months from baseline. Progression indicators map the
features in the original dataset to the progression space, via which we identified memory and
cognitive decline as the two dimensions of the modeled AD progression space. The relative
position along the x- and the y-axis represent worsening sleep or memory disorder.
Figure 3.1: Workflow of analysis and model development.
Next, unsupervised clustering via GMM [88] was used to define the hidden subtypes
within the MCI and dementia patients. GMM is an expectation-maximization algorithm
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that maximizes the likelihood of observing the data, given the underlying parameters of
the distribution. Bayesian information criterion (BIC) [90] was used to select the optimum
number of underlying clusters for the GMM. BIC is a maximum likelihood estimate which
tries to select the best model among the given set of candidates. In all the scenarios, three
optimum number of clusters, defined as low, moderate (medium) and high progression rates,
were attained. After obtaining the AD progression space and classifying MCI and dementia
patients into different progression groups, the performance of various supervised learning
classifiers (namely ensemble random forest, linear discriminant analysis, Naive Bayes, adap-
tive boosting, nearest neighbors, logistic regression and decision trees) were compared to
predict a participant’s progression stage after 24 and 48 months from baseline using read-
ings up to 12 months. Two models were built a) Model 1: predict progression at 24th month
after baseline by using baseline and first-year factors b) Model 2: predict progression at
48th month after baseline by using baseline and first-year factors. Recurrent neural network
(RNN) architecture with LSTM was also used to predict the progression rates (control, low,
moderate, and high) after 24 and 48 months from the baseline. The LSTM architecture had
a single LSTM bidirectional layer connected to a fully connected layer. Cross entropy loss
function was used at the output layer since it combines both logs of softmax and negative
log-likelihood loss functions. Optimal parameters for the models were found to be a single
hidden layer with 128 hidden units with a learning rate of 0.001 and a dropout probability
of 0.2. Since our dataset size was limited in terms of the number of observations, five-fold
cross-validation (CV) was used to evaluate the models. Among all the explored algorithms,
a random forest classifier [91] gave the best five-fold CV accuracy. Hence, parameters for
the random forest algorithm were fine-tuned using grid search (4800 iterations) and five-fold
CV.
3.2.4 Model evaluation
Two different evaluation metrics were used for validating the clustering and prediction
models. Sensitivity and specificity are measures of the proportion of positives that are
correctly identified and negatives that are correctly identified, respectively. The plot of
sensitivity on the y-axis and (1 − specificity) on the x-axis is called the area under the
receiver operating characteristic (AUC of ROC) curve with a greater value representing a
better clustering model. AUC of ROC was used to evaluate the clustering algorithms. Since
this is a multi-class problem, one versus all approach was used to calculate the AUC for each
class. Next, a five-fold CV was used to judge the performance of the proposed prediction
models. The model was repeatedly trained on four parts, and accuracy for prediction was
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calculated on the fifth part with a random selection of partitions each time.
3.2.5 Trajectory prediction
NMF was used to project the observations in progression space. LSTM was used to predict
the position of patients in the progression space (trajectory prediction) at the 24th and 48th
month using data collected at baseline and after 6 and 12 months from baseline. For this
study, five separate projections were made using data until each visit and projections at the
24th and 48th month were predicted. A bidirectional LSTM with two layers consisting of 32
hidden units was trained for 50 epochs with a learning rate of 0.001 and a batch size of 10
for the same. Since the projection was made in the 2D axis, the mean Euclidean distance
was used to assess the performance of this model. Only the features which were present for
all the first three visits (baseline, m06, and m12 visits) were considered for this study.
In the subsequent analysis, we study the share of different frequencies of APOEε4 variants
for each progression subtype since APOEε4 genotype is known to be closely related to AD
risk [117]. Further, we discuss the reversion from AD to MCI and MCI to control stage
captured in the proposed progression space and correlation of a participant’s AD progression
stage with their age, educational status, APOEε4 gene, and other selective critical features.
3.3 RESULTS
We have two progression indicator vectors in the reduced 2D ADNI progression space.
The features observed in the real data were correlated to the two axes of the progression
space using the magnitude of coefficients observed in the progression indicator vectors. A
higher magnitude corresponding to the first progression indicator vector will correlate the
feature to the first axis and similarly for the second axis.
3.3.1 ADNI progression space
Progression indicator i.e., coefficient matrix obtained from the NMF, was used to find out
the hidden features that each of the two axes of the reduced space represents. Progression
indicator vectors represent latent features of the reduced progression space. Progression
indicator coefficients for each feature are plotted in Figure 3.2, and they are separated by
drawing a line with slope 1. Features that occur below this separating line were associated
with cognitive decline (x-axis) in the AD projection space, and features that lie above the
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control low moderate high
M24 84.98± 5.97 0.94± 0.03 0.90± 0.05 0.94± 0.03 0.98± 0.01
M48 79.75± 4.25 0.92± 0.02 0.83± 0.06 0.90± 0.04 0.96± 0.04
line were associated with memory decline (y-axis) in the AD progression space. Features
close to the separating line were not associated with any axis.
This transformed data was used to project the participant’s disease progression stage at
the 24th (Figure 3.3) and the 48th month (Figure 3.4).
Further, three different zones, namely low, moderate, and high progression rates, were
identified in the MCI and dementia patients at 24th and 48th month, as depicted in Figure
3.5.
The progression rate of participants after the 24th and 48th months from the baseline were
predicted using the random forest classifier. It gave the best five-fold cross-validation accu-
racy and area under ROC curve results for all the cases. For the 24th month using baseline
and 12 months of observations, AUC of 0.94 (95% CI, 0.91-0.97), 0.98 (95% CI, 0.97-0.99),
0.90 (95% CI, 0.85-0.95) and 0.94 (95% CI, 0.91-0.97) for controls, high, low and moderate
progression rates were observed respectively. Prediction of progression at 48th month using
baseline and 12 months of observations yields AUC of 0.92 (95% CI, 0.90-0.94), 0.96 (95%
CI, 0.92-1.0), 0.90 (95% CI, 0.88-0.92) and 0.83 (95% CI, 0.77-0.89) for controls, high, low
and moderate progression rates respectively. In our implementation, the accuracy for the
prediction of progression at the 24th and 48th month is 83.60% and 77.33% respectively (Ta-
ble 3.1). Figure 3.6 depicts the ROC curves for 4 separate classes (controls, low, moderate
and high progression rates) for the 24th and 48th month.
LSTM model was also used for the prediction of AD subtypes with low, medium, and high
progression rates as well as controls. The accuracy of prediction of projection rates using
LSTM is 75.91% and 81.77% for the 48th and 24th month respectively. The performance of
the neural network did not match other more traditional methods because of small sequence
length, a smaller number of features, and a limited number of participants in the dataset.
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Figure 3.2: The plot of features in two dimensions using progression indicator vectors.
Features in red correspond to memory decline and features in blue correspond to cognitive
decline. Yellow line with a slope of 1, which separates the features into two categories, is
drawn for reference.
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Figure 3.3: Comparison of 24th month machine learning based prediction and original labels.
A total of 453 cases are projected in the AD progression space at the 24th month. Left:
Machine learning based classification. Right: Colored with original labels.
Figure 3.4: Comparison of 48th month machine learning based prediction and original labels.
A total of 247 cases are projected in the AD progression space at the 48th month. Left:
Machine learning based classification. Right: Colored with original labels.
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Figure 3.5: Three different progression rates are identified in MCI and dementia patients.
Left: at the 24th month. The low, moderate and high progression rate zones are represented
in red, blue and green respectively. Right: at the 48th month. The low, moderate and high
progression rate zones are represented in red, blue and green respectively.
Figure 3.6: ROC of AD patient’s progression rate after the 24th and 48th months based
on the baseline data. Including the area under the ROC for 4 AD progression subtypes
(controls, low, moderate and high progression rates). Left: The predictions for the disease
stage at the 24th month were made using a random forest algorithm. Right: The predictions
for the disease stage at the 48th month were made using random forest algorithm.
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3.3.2 Trajectory prediction using LSTM networks
Since no therapies in AD modification are known yet, predicting the trajectory of AD
progression at the early disease stage may offer a practical tool for refined clinical trials
testing novel disease-modifying strategies. Figure 3.7 represents the predicted and projected
values in the AD progression space for one of the participants.
Figure 3.7: The predicted and projected trajectories of AD progression using LSTM for an
AD patient.
NMF was used to project the data in progression space for each visit. The data from the
first three visits were used to predict the position of an observation in progression space for
the next two visits (visit at 48th and the 24th month). The mean Euclidean distance between
projected and predicted test observations in the projection space (quantifying the model
performance) for the 48th and the 24th month are 0.00206 and 0.00164 respectively. The
number of participants in each cohort was limited, and not all the features were ascertained
in all three (baseline, after 6 and 12 months) visits. These limitations affected the model
performance.
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Table 3.2: Number of MCI and dementia patients in each subtype.
Low Moderate High
MCI 124 69 4
Dementia 1 42 43
3.3.3 Statistics of each progression subtype
The number of subjects with MCI, dementia, and controls in each subtype is shown in
Table 3.2. Figure 3.8 shows their share percentage in each of the subtypes present after
24 months from baseline. As expected, the share of dementia patients is maximum at a
high progression rate. The low progression rate has no dementia patient and contains only
MCI patients. The moderate progression rate subtype is dominated by MCI patients, which
covers around 83% of the observation in that subtype. A similar trend was observed after
48 months from baseline as well.
Figure 3.8: Percent share of controls, MCI and dementia patients for different subtypes
present after 24 months from baseline. The share of MCI patients is decreasing with an
increase in progression rate.
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3.3.4 Percent share of APOEε4 variants for different subtypes
APOE has three common alleles, ε2, ε3, and ε4, of which the ε4 allele is closely associated
with increased risk of AD [117]. The distribution of APOEε4 alleles for each progression
rate subtype is shown in Figure 3.9 after 24 from the baseline. This figure illustrates that
the progression rate increases with the number of APOEε4 alleles.
Figure 3.9: Percent share of APOEε4 alleles for different subtypes after 24 months from
baseline. The share of 0 occurrences of APOEε4 alleles is decreasing with an increase in
progression rate, whereas the share of 1 and 2 occurrences are increasing.
3.4 DISCUSSION
In this section, we study the reversion of AD captured in the constructed progression space,
correlation between the APOEε4 genetic variants and participant’s progression state, effects
of aging on AD progression in controls, correlation of memory decline in AD patients with
their educational and occupational attainments and distribution of projected dimensions
(memory decline and cognitive decline) for each AD subtype, correlation between certain
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selective features and AD progression rates in the following subsections. To conclude, we
discuss some of the future directions to extend the proposed study.
3.4.1 AD progression space and disease reversion
Since ADNI is a longitudinal study, the disease state of patients is reassessed every 12
months. The clinical condition either deteriorated or stayed the same for most of the patients,
but in rare instances, it reversed to a better state, i.e., some patients were observed moving
from dementia to MCI or MCI to control stage. These observations were plotted to assess the
robustness of the constructed progression space. Figure 3.10 plots these reversion cases at the
24th and 48th month. It can be verified from these figures that patients moving from dementia
to MCI fall in the intermediate region between dementia and MCI (moderate progression rate
region). Similarly, patients moving from MCI to control lie in the intermediate progression
region between them. Thus, the progression space captures the reversion of the disease state.
Figure 3.10: Label Reversions (only MCI to control and dementia to MCI). Left: The
positions of the reversions at 24th month relative to all other observations. Right: The
positions of the reversions at 48th month relative to all other observations.
3.4.2 AD progression states and APOEε4 allele counts
To understand the underlying biological patterns among patients in the progression space,
we plotted the distribution of the APOEε4 alleles. Figure 3.11 projects the observations with
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0 and 2 counts of APOEε4 variants on the AD progression space at 24th and 48th month.
It is evident from these figures that observations with a 0 count for the APOEε4 allele are
concentrated towards the low progression rate zone, whereas observations with two counts
of APOEε4 allele are concentrated towards the moderate and high progression rate zones.
This observation further validates the existing literature [118] and confirms a significant cor-
relation between APOEε4 with cognitive performance.
Figure 3.11: Projection of the number of APOEε4 variants on the projection space. x-axis
and y-axis have visualizations of the distribution of APOEε4 alleles in those directions. Left:
at 24th month. Right: at 48th month.
3.4.3 AD progression in controls and aging
In Figure 3.12, progression can also be seen in control observations at 24th and 48th month
respectively, attributed to a decline in normal cognition and memory with increasing age of
the participants. Since this decline is not severe, the observations do not lie in moderate
or high progression rate zones. A simple clustering of observations into two clusters shows
a stark difference in the mean age of the clusters. It is interesting to note that the mean
age for the cluster, which is relatively close to the moderate progression rate zone is 74.59
years and the mean age of the cluster away from this zone is 72.15 years. Similarly, for the
48th month, the mean age of the two clusters relatively close and away from the moderate
progression zone are 71.53 and 73.51, respectively (Figure 3.12).
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Figure 3.12: Aging pattern in controls. Mean age of cases in the two clusters of controls.
Clusters represent an aging pattern in controls. The cluster near moderate progression rate
zone has a high mean age than one which is away from it. Left: at 24th month. Right: at
48th month.
3.4.4 Memory decline in AD patients and educational acquirements
To further discover a generalized trend in the AD progression rate, a polynomial curve was
fitted on the projected observations. BIC was used to find out the optimum degree of the
fitting polynomial, which was observed to be three. As seen in Figure 3.13 (Left), the cubic
curve fits the data in a linear fashion in the low progression region. However, it deviates
slightly from this linear behavior in high and moderate progression region. The magnitude
of the slope of the linear curve is 1.19 indicating a rapid memory decline as compared to cog-
nitive. The slope of the progression for 200 most and least educated observations is shown
in Figure 3.13 (Right). The magnitude of slope for the linear curve is 1.26 and 1.19 for
highly educated and less educated patients, respectively. As the slope for highly educated
patients is greater than the slope for less-educated patients, it can be inferred that there
is a relatively rapid decline in memory of patients with higher education. A study on the
links between education and memory decline in AD was carried out in [119]. The research
concluded that memory declined more rapidly in AD patients with higher educational and
occupational attainment. Thus, our results are further validated by these explorations done
in the previous research [119].
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Figure 3.13: Memory decline in AD patients and educational acquirements. Left: Linear and
cubic curve-fitting on 582 observations projected on the progression space. The magnitude
of the slope of the linear curve is 1.19 indicating a rapid memory decline as compared to
cognitive. Right: Linear curve fitting for 200 most educated and 200 least educated patients.
3.4.5 Distribution of memory and cognitive decline
Figure 3.14 shows the distribution of projected dimensions (memory decline and cognitive
decline) for each AD subtype after 24 and 48 months. In the progression space, along
the positive direction of the y-axis, the memory decline increases, and along the negative
direction of the x-axis, the cognitive decline increases. A low value on the x-axis indicates a
higher cognitive decline, whereas a high value on the y-axis indicates higher memory decline.
High progression rate has the highest memory and cognitive decline, which goes on reducing
with a reduction in progression rate.
3.4.6 Selective features and AD progression rates
Figure 3.15 shows the distribution of the MMSE score after 6 and 12 months for each
AD subtype at the 24th month. Reduction in the MMSE score with increased progression
is observed. A similar trend is observed in the distribution of the MMSE score for each AD
subtype at the 48th month. Further, there is an increase in functional assessment question-
naire (FAQ) total score with increasing progression rate for the 24th and 48th month AD
subtypes as shown in Figure 3.15.
51
Figure 3.14: Distribution of projected dimensions (cognitive and memory decline) for each
AD progression subtype. A lower numeric value on the cognition axis indicates high cognitive
decline whereas a higher numeric value on the memory axis indicates high memory decline.
A similar relationship can be observed in the figures. Left: after 24 months from baseline.
Right: after 48 months from baseline.
3.4.7 Limitations and future directions
In this work, we discussed the share of different APOEε4 genotype for each progression
rate and its correlation with cognitive performance. Future work should involve examining a
few other genes that also have been closely related to the progression of AD for studying their
interactions [120, 121]. As stated earlier in the paper, AD risk is associated with APOEε4
gene variants [117]. However, the progression space was constructed using only the time-
variant clinical data. Therefore, APOEε4 data were not considered during the construction
of the projection space. Moreover, the diagnosis of participants (control, MCI, AD) in the
ADNI study is based on their clinical examinations, having a sensitivity of 70.9-87.3% as
compared to the neuropathologic assessments, which are considered the gold standard for
AD identification [122]. Hence, the discussed progression models suffer from the implicit
noise involved in the diagnosis of the study participants. For future analysis, involving di-
agnosis with neuropathologic examinations may help scale down the ambiguity involved in
the true status of participants [121].
The present analysis can be continued in various directions. Since both AD and PD
are neurological diseases with AD primarily affecting memory advancing to influence mo-
tor functions and PD impacting movement and coordination progressing to hinder memory
and other cognitive processes, exploring to project ADNI with a PD dataset might explain
features responsible for PD progressing to AD or vice versa. Moreover, this study involved
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Figure 3.15: Distribution of the MMSE score for each AD subtype (subtypes at 24th month).
MMSE score decreases with an increase in progression rate. Right: Distribution of FAQ
total score for each AD subtype (subtypes at 24th month). FAQ total score increases with
an increase in progression rate.
investigations only considering the clinical data for exploring AD progressions. Integrating
further information such as neuroimaging or biomarker data may augment additional infor-
mation in our analysis. Since we relied on the CV to gauge the performance of our models,
validating the study on separate AD datasets such as AMP-AD [123] when it becomes avail-
able. Finally, the discussed analysis only focused on predicting progression space in AD.
The proposed framework can be further adapted to study additional kinds of dementia, such
as frontotemporal degenerations, Lewy body dementia, multi-infarct dementia, etc.
3.5 SUMMARY
This work clusters participants in distinct progression stages of AD and discusses an ap-
proach to predict the future rate of progression after the 24th and 48th months from baseline
using longitudinal clinical data. Predicting disease progression serves as a paramount chal-
lenge in the therapy and cure of several elaborate diseases. This study is a step forward
towards designing sophisticated machine-learning paradigms to facilitate early diagnosis of
AD progression. Predicting AD progression rates would lead to better patient-specific at-
tention by recognizing at an early stage the patients with a swift rate of progression. The
proposed disease progression and trajectory prediction algorithms can help doctors and prac-
titioners develop a methodical and organized course for clinical tests, which can be much
more concise and effective in detection. These adaptations and modifications in clinics may
help to diminish treatment and therapy costs for dementia. Further, no healing treatments
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in AD modification exist. Hence, the capability to anticipate the trajectory of impending
AD progression at the early stages of the disease is an advancement towards uncovering
novel treatments for AD modification. The proposed analysis provides insights to inhibit
or decelerate the progression of AD-related symptoms and subsequent deterioration in the
characteristics of life that are accompanied by the disease.
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CHAPTER 4: LEARNING AMYOTROPHIC LATERAL SCLEROSIS (ALS)
In this chapter, we review the work on Identification and prediction of ALS subgroups
through unsupervised and semi-supervised machine learning. Similar to Alzheimer’s and
Parkinson’s chapters, we use an unsupervised learning approach to identify new subtypes.
However, unlike Parkinson’s and Alzheimer’s, which have a long multi-year course, we do
not predict progression. Since ALS is a rapidly progressive disorder, we focus on subtype
identification and survival analysis. We also use semi-supervised learning for enhancing sub-
type identification. A subset of this work was published previously as [52, 53, 54].
Amyotrophic lateral sclerosis is not a single entity, but rather represents a collection of
syndromes in which the motor neurons degenerate. Synergistic with these multiple genetic
etiologies, there is a broad variability in the clinical manifestations of the disease in terms
of ages of symptom onset, site of onset, rate and pattern of progression, and cognitive in-
volvement. Due to these variable presentations, counseling of patients about their individual
risks and prognosis is limited. There is an unmet need for predictive tests that facilitate
early detection and characterization of distinct disease subtypes as well as improved, indi-
vidualized predictions of the disease course. The emergence of machine learning to detect
hidden patterns in complex, multi-dimensional datasets provides unparalleled opportunities
to address this critical need.
We used unsupervised and semi-supervised machine learning techniques to explore the
clinical patterns of disease within a deeply-phenotyped, population-based collection of ALS
patients. Our analysis distinguished distinct disease subtypes with a highly predictable site
of onset. We have demonstrated robust replication of these findings in the independent val-
idation cohort.
These data-driven results enable clinicians to deconstruct the heterogeneity within their
patient cohorts. This knowledge could have immediate implications for clinical trials by im-
proving the detection of significant clinical outcomes that might have been masked by cohort
heterogeneity. We anticipate that machine learning models will improve patient counseling,




Although widely considered to be rare, amyotrophic lateral sclerosis (ALS, OMIM #105400)
is one of the most common forms of neurodegeneration in the general population, accounting
for approximately 6,000 deaths in the United States and 11,000 deaths in Europe annually
[124, 125]. Characterized by progressive paralysis of limb and bulbar musculature, it typi-
cally leads to death within three to five years of symptom onset. Medications only minimally
slow the rate of progression, and, as a consequence, treatment is primarily focused on symp-
tomatic management.
Genetic advancements have shown that ALS is not a single entity, but rather represents a
collection of syndromes in which the motor neurons degenerate [126]. Synergistic with these
multiple genetic etiologies, there is a broad variability in the clinical manifestations of the
disease in terms of ages of symptom onset, site of onset, rate and pattern of progression,
and cognitive involvement. This clinical heterogeneity has hampered efforts to understand
the cellular mechanisms underlying this fatal neurodegenerative syndrome, and has hindered
clinical trial efforts to find effective therapies [127].
Given the importance of this clinical heterogeneity, it is not surprising that there have
been myriad efforts to develop classification systems for ALS patients over the years. Ex-
amples include categorization based on family status [128], categorization based on clinical
milestones [129], based on neurophysiological measurements [130, 131] and categorization
based on the certainty of diagnosis [132]. The ability to identify the true number and type
of subgroups with the ALS population and the capacity to reliably assign patients to these
distinct subgroups would be a major step forward for the field. Though broadly useful, each
of these existing classification systems suffer from a central problem, namely that it is un-
clear if they identify meaningful subgroups within the ALS population, or merely represent
human constructs applied to the data based on preconceived notions.
Here, we applied novel unsupervised and semi-unsupervised machine learning techniques
to explore the clinical patterns of disease within a deeply-phenotyped, population-based col-
lection of ALS patients. With the unsupervised machine learning approach, our goal was
to determine what subtypes of the disease might exist within this patient population and
to see if we could reliably predict which subgroup an ALS patient might belong to. This
process produced a multi-dimensional space that captures the topological and relative rela-
tionships of the ALS subtypes, mapping similar cases close together. The key advantage of
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this machine learning approach is the ability to identify complex relationships in a uniquely
unbiased and data-driven manner that moves beyond the traditional univariate approach.
Identified the ALS subtypes with the unsupervised learning approach, we then utilize the
semi-supervised learning approach. We incorporated the physician’s assessment of patients
for the predictive task. With the trained model, we dissected the machine learning model
to realize the underlying ALS structure which machine has learned. This representation is a
close proxy to what the model “thinks” about data for it to classify patients as observed by
the physician a year into the disease. Resulting in a more fine-tuned representation of ALS
subtypes compared to the fully unsupervised.
Following the successful presentation of ALS subtypes, we built baseline predictor mod-
els using a supervised machine learning approach. These baseline predictors accurately
predicted an individual patient’s age of symptom onset and prognosis, a key concern when-
ever an individual is diagnosed with ALS. Such algorithms could provide a standardized
approach to disease classification that minimizes inter- and intra-rater variability, which
hampers multi-center clinical trial efforts.
4.2 METHODS
4.2.1 Study participants
The Piemonte and Valle d’Aosta Register for Amyotrophic Lateral Sclerosis (PARALS)
[133] was used as the discovery cohort. PARALS included 2,858 patients who had been di-
agnosed with ALS according to El Escorial criteria [132], and represented incident cases who
had been enrolled in Piedmont and Valle d’Aosta Registry for ALS between January 1, 1995,
and December 31, 2016. Established in 1991, this population-based registry prospectively
ascertains ALS cases within two regions of Northwestern Italy that include Turin and has
a catchment population of nearly 4.5 million inhabitants [133]. Patients are followed longi-
tudinally over the course of their illness, allowing the course of their illness to be observed.
Informed written consent was obtained from all participants, and the study was approved
by the ethics committee of A.O.U. City of Health and Science of Turin.
The replication cohort consisted of 1,097 patients who had been diagnosed with ALS
according to the El Escorial criteria and represented incident cases who had been enrolled
in the Emilia Romagna Region (ERR) ALS registry between January 1, 2009, and March
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1, 2018. This registry prospectively collects demographic and clinical data on ALS cases
incident within a Northwestern region of Italy that includes Modena and Bologna [134].
Similar to PARALS, the catchment population is 4.4 million, and patients are followed
in a longitudinal manner. The methods for collecting clinical and demographic data are
standardized across the PARALS and the ERR registries to facilitate comparisons between
these two large epidemiological efforts. Informed written consent was obtained from all
participants, and the study was approved by the ethics committees of the coordinating
center and of the nine provinces of ERR.
4.2.2 Clinical data
For each cohort, a comprehensive and shared set of collected common data elements were
selected for analysis. Table 4.1 provides a list of all clinical features as well as the analytical
method they were used in.
Table 4.1: List of clinical parameters used in each stage of analysis.
Begin of Table 4.1
















1 Cancer Yes Yes Yes
2 Cancer type No, due to irrel-
evance
No No
3 Hypertension Yes Yes Yes
4 Hyperthyroid Yes Yes Yes
5 Hypothyroid Yes Yes Yes
6 Diabetes Yes Yes Yes
7 COPD Yes Yes Yes
8 Smoker No, due to high
missingness
Yes Yes Yes
9 Parkinsonism Yes No Yes
10 Corea Yes No Yes
11 Ataxia Yes No Yes
12 Marital status Yes Yes Yes
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Table 4.1 (cont.)
















13 Education Yes Yes Yes
14 Cognitive status1 No, due to high
missingness
No, due to high
missingness
No, due to high
missingness
15 Cognitive status2 No, due to high
missingness
No, due to high
missingness




No, due to high
missingness
No, due to high
missingness
No, due to high
missingness
17 Initial Dx was
PLS
No, due to po-
tential bias
Yes No No
18 elEscorial at Dx Yes Yes Yes
19 elEscorial2 No, due to irrel-
evance
No, due to irrel-
evance
No, due to irrel-
evance
20 elEscorial3 No, due to irrel-
evance
No, due to irrel-
evance
No, due to irrel-
evance
21 FVC percent at
Dx
Yes Yes Yes
22 Height Yes Yes Yes
23 Weight at Dx Yes Yes Yes
24 BMI at Dx Yes Yes Yes
25 Weight 2 years
prior to illness
Yes No Yes
26 BMI 2 years prior
to illness
Yes No Yes
27 Rate of decline
BMI per month
Yes No Yes
28 PEG inserted No, due to possi-
ble data leakage
Yes No Yes
29 PEG days into ill-
ness
No, due to possi-
ble data leakage
No Yes





















31 BIPAP days into
illness
No, due to possi-
ble data leakage
No Yes
32 Tracheostomy No, due to possi-
ble data leakage
Yes No Yes
33 Trach days into
illness
No, due to possi-
ble data leakage
No Yes
34 Place of birth No Yes No No
35 Place of residence No Yes No No
36 Family history of
ALS
Yes Yes Yes
37 c9orf72 status No, due to possi-
ble data leakage
Yes Yes Yes
38 Mutation present No, due to po-
tential bias
Yes Yes Yes











42 Site of onset Yes No Yes
43 Onset side Yes No Yes
44 Clinical type at
onset
No, due to high
missingness
Yes No Yes
45 Clinical type at
one year
No, due to data
leakage
Yes No Yes
46 Sex Yes Yes Yes
47 Age at onset Yes Predicting it Yes
48 Age at diagnosis Yes No Yes
49 Delay in Dx days Yes No Yes
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Table 4.1 (cont.)
















50 Survival days No, due to data
leakage
No Predicting it
51 Vital status No, due to data
leakage
No No
52 ALSFRS1 Yes Yes Yes
53 ALSFRS2 Yes Yes Yes
54 ALSFRS3 Yes Yes Yes
55 ALSFRS4 Yes Yes Yes
56 ALSFRS5 Yes Yes Yes
57 ALSFRS6 Yes Yes Yes
58 ALSFRS7 Yes Yes Yes
59 ALSFRS8 Yes Yes Yes
60 ALSFRS9 Yes Yes Yes
61 ALSFRS10 Yes Yes Yes
62 ALSFRS11 Yes Yes Yes
63 ALSFRS12 Yes Yes Yes










End of Table 4.1
4.2.3 Outcome measures
Each patient in the discovery and replication cohort was assigned to one of six clinical subtypes
(bulbar ALS, respiratory ALS, flail arm ALS, classical ALS, pyramidal ALS, and flail leg ALS)
based on the classification system published by Chiò and colleagues [129]. In contrast to other
classification systems, these subtypes are determined based on clinical features of the patient one
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year after symptom onset. We compared the subtype clusters defined by our unsupervised ma-
chine learning approach to the clinical subtype assigned by the Chiò classification system. For this
reason, the clinical subtypes assigned by the Chiò classification system were not entered into the
machine learning algorithm.
Age at symptom onset was defined as the age of the patient when they first developed symptoms
of weakness in their bulbar, respiratory, or limb muscles. Survival time was defined as the number
of days from symptom onset to (a) death; (b) tracheostomy and permanent ventilation; or (c) date
of the last followup if the patient was still alive.
4.2.4 Filtering of clinical data
Clinical data were filtered prior to analysis. Features that are not meaningful for subtyping of
the ALS patients (e.g., cancer type, place of birth) or that could introduce bias (e.g., tracheostomy,
initial Dx was PLS) were omitted from the analysis. Samples with missing values (n = 497 in the
discovery cohort, n = 108 in the replication cohort) in the revised ALS Functional Rating Score
(ALSFRS-R) were also omitted, as this parameter was found to be a powerful predictor of subtype.
As machine learning methods used in this paper only accept numeric input and are sensitive to
input scaling, categorical features were one-hot encoded. Min-max normalization was also applied
to numeric features to preserve the shape of the distribution and ensure they were within a zero to
one range. Ultimately, 2,361 cases in the discovery cohort and 989 in the replication cohort pass
the filtering step.
4.2.5 Data imputation
After filtering, no missingness was found in most features except in FVC percent at Dx, BMI
2 years prior to illness, rate of decline BMI per month, weight two years prior to illness, BMI at
Dx, height, and weight at Dx. These features were missing at random with missingness of 15-20%.
We used the k-Nearest Neighbor (kNN) imputation method with k = 5 neighbors to preserve the
clusters [135].
4.2.6 Unsupervised subtype identification using Uniform Manifold Approximation and
Projection
We used an unsupervised clustering approach to identify ALS subtypes. We applied Uniform
Manifold Approximation and Projection (UMAP) to processed data. UMAP [136] is a machine
learning approach that is primarily used for non-linear dimension reduction. UMAP produces a
data embedding by searching for a low dimensional projection of the data that has the closest
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possible equivalent fuzzy topological structure. This non-linear dimension reduction preserves
the local and global structures existing within the data, along with reproducible and meaningful
clusters.
4.2.7 Semi-supervised subtype identification using multilayer perceptron neural network
To enhance our ability to resolve the different types of spinal-onset ALS, we pre-processed the
data using a multilayer perceptron neural network consisting of five hidden layers with 200, 100,
50, 25 and 3 neurons 4.1. This supervised technique reduced the 72 input clinical features of our
dataset down to three dimensions. The dimension-reduction network was trained on the ‘clinical
type at one-year’ feature using a Softmax classifier. After training the network with ten-fold cross-
validation, the data is then once more used as input for the forward loop of the network. This time,
the last hidden layer activations, which represent a dimension reduction from 72 to 3 dimensions,
were used as input for the next t-SNE algorithm to improve the separation of the clusters further.
Figure 4.1: Architecture of the multilayer perceptron neural network (MLP) used for the
semi-supervised subtype identification of ALS. The neural network consists of five hidden
layers with 200, 100, 50, 25, and 3 neurons. After training the network with ten-fold cross-
validation, the activations of the last hidden layer are used as input for the next algorithm,
t-SNE. The network compresses the data to 3 dimensions, acting as a dimension reduction
technique.
t-distributed Stochastic Neighbor Embedding (t-SNE) [137] is a machine learning approach that is
primarily used for the visualization of high-dimensional data within a lower-dimensional manifold.
It calculates the pairwise densities of the data points in the original and the reduced space and then
minimizes the difference between both densities. This non-linear dimension reduction preserves the
local and global structures existing within the data.
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4.2.8 Supervised prediction of the age of symptom onset and survival time
We assessed the ability of three supervised machine learning algorithms (Random forest [91],
LightGBM [138], and XGBoost [139]) to predict the age of symptom onset and to predict survival
time. Random forest algorithms leverage decision trees by training a high number of them in par-
allel and then evaluating the combined result. Each tree is trained on a randomly sampled subset
of the training data, and at each additional randomness is added by sampling from the possible
features to split on. This added randomness through the data and feature bagging ensures variance
in the different trees. The results of the trees are then averaged to get a final prediction.
LightGBM and XGBoost are gradient boosting algorithms. Contrary to the random forest, who
builds a multitude of trees in parallel, gradient boosting works by combining learners in sequence.
In the following, the used learners are decision trees. Decision trees that usually are not to their
maximum depth developed, called weak learners, are trained on the residuals of their predecessors,
thereby putting emphasis on the previous misclassification.
The validity of the approach was assessed by dividing our cohort between a training dataset and
a test dataset. Hyperparameters were tuned on the training cohort using five-fold cross-validation.
Four of those were used as a training set for optimization, while the fifth is used as a validation set
to check the results. To tune the hyperparameters, we build a grid of possible parameter combina-
tions and use a randomized grid search to find a good combination that maximized the validation
accuracy. Finally, a model was trained using the complete training dataset and the optimal hyper-
parameter combination, and then evaluated on the test set.
SHAP (SHapley Additive exPlanations) approach [140]. SHAP is a unified approach to explain
the output of any machine learning model by assigning each feature an importance value based on
the Shapley value. Shapley values are used in game theory to determine the contribution of players
to success.
4.3 RESULTS
4.3.1 Identification of ALS subtypes
We applied unsupervised and semi-supervised machine learning approaches to our large dataset
consisting of 72 clinical features collected from 2,858 patients diagnosed with ALS obtained from
a prospective, population-based registry over a ten-year period. To do this, we used an unsuper-
vised UMAP algorithm alongside with semi-supervised approach of pre-processing the data with a
multi-layered perceptron neural network and using the dimension-reduced output as the input for
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the t-SNE algorithm. Both approaches were able to define distinct clusters of patients, represent-
ing subtypes of ALS. Figure 4.2 left column shows the result of the machine-learned topologies.
These projections show the relative distance of each patient in terms of their disease characteris-
tics. Patients have formed into multiple global and local clusters. By color-coding the patient’s
clinical type at one year according to the Chiò classification system, comparison showed that each
of these clusters corresponded to one of the six clinical subtypes previously defined by the Chiò
classification system (bulbar ALS, respiratory ALS, flail arm ALS, classical ALS, pyramidal ALS,
and flail leg ALS).
In order to ensure the generalizability and validity of the results, we replicate the ALS subtype
identification in the independent replication cohort. Figure 4.2 right column shows the identified
subtypes in the independent replication cohort. We see that the identified subtypes in the replica-
tion cohort are similar to the ones in the discovery cohort. The discovery and replication cohorts
are clinically different cohorts and recruited from different populations. The replication of our re-
sults in the replication cohort that was recruited with a different protocol shows the strength of our
study’s methodology. We demonstrate that if we ascertain the same phenotypes using standardized
scales, we can reliably discern the same subtypes. This makes our results robust, generalizable,
and the clinical subtypes reproducible.
While using the aforementioned unsupervised learning approaches, we were able to visualize,
cluster, and interpret ALS clusters, interpretability of the reduced dimensions remain difficult.
Most algorithms must make trade-offs, and our utilized methods are no exception. Most non-linear
dimension reduction techniques, including t-SNE and UMAP, lacks the strong interpretability of
reduced dimensions. On the other hand, linear transformations such as Principal Component
Analysis (PCA) and Non-Negative Matrix Factorization (NMF) produce interpretable reduced
dimensions but are unable to capture relationships between complex clinical phenomena accurately.
In particular, the dimensions of the UMAP embedding space have no specific meaning, unlike PCA
where the dimensions are the directions of greatest variance in the source data.
4.3.2 Prediction of survival time for patients diagnosed with ALS
Next, we applied machine learning approaches to predict survival time among ALS patients. The
most accurate survival prediction was provided by XGBoost modeling that incorporated the clinical
subtype identified by our earlier analysis (mean absolute error = 378.1 days). We determined the
clinical features that influenced survival using the SHAP approach that is designed to identify
complex relationships in multi-dimensional datasets (Figure 4.3). Although the various features
interact with each other within the model in a compound manner, some simple observations can
be made. The most influential feature on prognosis was the rate of decline in ALSFRS score per
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Figure 4.2: Identified ALS subtypes in the discovery and replication cohorts. Left column
shows the projections of the discovery cohort and right column projections of the replication
cohort. Each row corresponds to the utilized machine learning technique. Patients are color-
coded with the clinical type at one year, according to the Chiò classification system. The
comparison shows that each of these clusters corresponded to one of the six clinical subtypes
previously defined by the Chiò classification system (bulbar ALS, respiratory ALS, flail arm
ALS, classical ALS, pyramidal ALS, and flail leg ALS).
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month, a widely accepted indicator of disease progression rate with higher values associated with
poorer prognosis. The next most influential feature was the number of days after symptom onset
that the ALSFRS scoring was first conducted. This variable acts as a surrogate for the delay in
diagnosis, a well-established predictor of survival in ALS. The third most influential feature was
the forced vital capacity percentage at diagnosis, a measure of remaining respiratory function with
lower values predicting a shorter survival time.
Figure 4.3: Clinical features influencing survival prediction. (Left) Bar plot showing the
most influential clinical features based on SHAP values for the XGBoost prediction algo-
rithm. (Right) Detailed view of the influence of clinical features on the XGBoost prediction
algorithm.
4.3.3 Prediction of the age of symptom onset
When predicting the age at the onset of ALS, XGBoost was again the best performing algorithm
(MAE = 7.7 years). The most important features of the prediction output were whether the
patient has hypertension and the degree of education (Figure 4.4). The observation that education
is associated with higher age at symptom onset is consistent with our recent publication describing
the protective effect of education on the risk of developing ALS based on linkage disequilibrium
regression score [53].
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Figure 4.4: (Left) Barplot of the mean absolute SHAP values of the features for the XGBoost
algorithm, showing the influence on the result for the biased case for predicting the age at
onset. (Right) Detailed view of the influence of features on the XGBoost prediction on the
unbiased data of the age at onset prediction.
4.4 DISCUSSION
There were two main obstacles to unraveling the clinical heterogeneity of ALS. First, there has
been a paucity of large enough clinical databases. The PARALS is a large, population-based reg-
istry of ALS collected over a ten year period. Second, the clinical heterogeneity was clearly multi-
dimensional and complex. Previous efforts based on univariate or incorporating a small number
of variables have been spectacularly unsuccessful. Here, we benefit from the recent development
of machine learning. Though it is a broad concept, the main benefit to us is that it reduces/deals
with the complexity of the dataset.
Using an unbiased, data-driven approach, we identified six subtypes of ALS within our large
discovery cohort and replicated these findings in an independent population-based cohort. These
subtypes corresponded to those previously defined by the Chiò classification system, demonstrating
the utility of that approach. The key difference of this classification system compared to others is
that it relies on observing the patient one year after symptom onset. This lag in assigning cate-
gories allows the patient time to declare their category. Notably, our new algorithm provides the
ability to predict the patient’s category at an earlier time point.
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It is notable that the machine learning algorithm arrived at the same conclusion as the Chiò
and colleagues. We do not maintain that the machine learning algorithm is better at defining
categories than this group of experienced ALS neurologist. Instead, we say that an unbiased,
data-driven approach designed at identifying relationships within high dimensional data arrived at
the same conclusion as Chiò and colleagues. Thus, we believe that our data provide prima facie
evidence that the Chiò classification system is identifying the true and meaningful subgroups that
exist within the ALS population.
4.5 SUMMARY
In this study, we addressed the complexities of ALS disorder. This work identifies the data-
driven subtypes of ALS and discusses an approach to predict the disease course. Predicting disease
subtypes serves as a paramount challenge in the therapy and cure of several elaborate diseases. This
study is a step forward towards designing sophisticated machine-learning paradigms to facilitate
early diagnosis of ALS. Predicting ALS subtypes would lead to better patient-specific attention by
recognizing at an early stage the patients with a swift rate of progression. The proposed disease
prediction algorithms can help doctors and practitioners develop a methodical and organized course
for clinical tests, which can be much more concise and effective in detection. These adaptations and
modifications in clinics may help to diminish treatment and therapy costs for ALS. Further, the
capability to anticipate the subtypes of ALS at the early stages of the disease is an advancement
towards uncovering novel treatments for ALS modification. The proposed analysis provides insights
to inhibit or decelerate the progression of ALS-related symptoms and subsequent deterioration in
the characteristics of life that are accompanied by the disease. In the future work, we will perform
an in-depth analysis of identified subtypes and their genetic profiles.
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CHAPTER 5: LEARNING INTENSIVE CARE UNIT (ICU)
In this chapter, we review the work on Analysis and prediction of unplanned intensive care unit
readmission1. Unlike previous chapters where the health issue has a multi-year course, in the
ICU, data is short-term. Short-term data such as sensory and monitoring device data has a high
frequency of data collection but with a time window of hours to days. Due to the data collection fre-
quency, different predictive machine learning methods are used to encapsulate the time-sensitivity
of small fluctuations in the patient’s status. This work was published previously as [55].
Unplanned readmission of a hospitalized patient is an indicator of patients’ exposure to risk and
an avoidable waste of medical resources. In addition to hospital readmission, intensive care unit
(ICU) readmission brings further financial risk, along with morbidity and mortality risks. Iden-
tification of high-risk patients who are likely to be readmitted can provide significant benefits for
both patients and medical providers. The emergence of machine learning solutions to detect hidden
patterns in complex, multi-dimensional datasets provides unparalleled opportunities for developing
an efficient discharge decision-making support system for physicians and ICU specialists.
We used supervised machine learning approaches for ICU readmission prediction. We used ma-
chine learning methods on comprehensive, longitudinal clinical data from the MIMIC-III to predict
the ICU readmission of patients within 30 days of their discharge. We incorporate multiple types
of features including chart events, demographic, and ICD-9 embeddings. We have utilized recent
machine learning techniques such as Recurrent Neural Networks (RNN) with Long Short-Term
Memory (LSTM), by this we have been able to incorporate the multivariate features of EHRs and
capture sudden fluctuations in chart event features (e.g. glucose and heart rate). We show that our
LSTM-based solution can better capture high volatility and unstable status in ICU patients, an
important factor in ICU readmission. Our machine learning models identify ICU readmissions at
a higher sensitivity rate of 0.742 (95% CI, 0.718-0.766) and an improved Area Under the Curve of
0.791 (95% CI, 0.782-0.800) compared with traditional methods. We perform in-depth deep learn-
ing performance analysis, as well as the analysis of each feature contribution to the predictive model.
This work highlights the ability of machine learning models to improve our ICU decision-making
accuracy and is a real-world example of precision medicine in hospitals. These data-driven solu-
tions hold the potential for substantial clinical impact by augmenting clinical decision-making for
physicians and ICU specialists. We anticipate that machine learning models will improve patient
counseling, hospital administration, allocation of healthcare resources and ultimately individualized
clinical care.
1This research was assisted by Yu-Wei Lin and Yuqian Zhou as documented in their thesis.
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5.1 INTRODUCTION
Unplanned hospital readmission is an indicator of patients’ exposure to risk and an avoidable
waste of medical resources. To address the unplanned readmission issue, in 2010, the Affordable
Care Act (ACA) created the Hospital Readmissions Reduction Program to penalize the hospitals
whose 30-day readmission rates are higher than expected [141]. According to data released by
the Centers for Medicare & Medicaid Services (CMS), since the program began on Oct. 1, 2012,
hospitals have experienced nearly $2.5 billion of penalties assessed on hospitals for readmissions,
including an estimated $564 million in fiscal year 2018, $144 million more than in 2016 [142].
In addition to hospital readmission, intensive care unit (ICU) readmission brings further financial
risk, along with morbidity and mortality risks [143, 144]. Premature ICU discharge may potentially
expose patients to the risks of unsuitable treatment, which further leads to an avoidable mortality
[145]. Reportedly, the mortality rates of ICU readmitted patients range approximately from 26%
to 58% [146, 147, 148]. Surprisingly, even in developed countries, hospitals suffer from high ICU
readmission rates, around 10% of patients will be readmitted back to ICU within a hospital stay
[143]. Moreover, there is an escalating trend in the U.S. for ICU readmission rates rising from
4.6% in 1989 to 6.4% in 2003 [144]. Thus, making ICU readmission rates one of the critical quality
indicators in the performance evaluation of ICU.
To reduce avoidable ICU readmission, hospitals need to identify patients with a higher risk of
ICU readmission [149]. Identified patients will stay longer in the ICU and will not be exposed to
readmission risks. Moreover, the additional medical resources that would have been used in un-
necessary readmission can be reallocated more efficiently considering the scarcity of ICU resources
compared to the general hospital. Ultimately, an efficient decision-making support system can have
significant impact by assisting hospitals and ICU physicians identifying patients with high readmis-
sion probability. We can use machine learning and artificial intelligence techniques to build such
decision-making support systems. Data-driven predictive models aimed at predicting ICU readmis-
sion may be built using various datasets including administrative claims [150, 151, 152], insurance
claims, and electronic health records (EHRs). Among these datasets, insurance claims are not
suitable for real-time prediction [153] electronic health records (EHR) have shown to provide ap-
propriate data for medical decision-making support solutions. A systematic review of readmission
prediction models [154], summarizes 26 unique readmission prediction models of which 23 models
rely on EHR including the most recent work on predicting all-cause 30-day readmission by Jamei
et al. [153] which proposed an accurate and real-time prediction model based on neural networks.
Even though multiple studies have developed predictive models to tackle the problem of identify-
ing patients with a high risk of readmission, we are still far from a comprehensive practical solution.
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Overall, these studies have five main drawbacks. First, the scope of some predictive models is lim-
ited to a specific disease or treatment rather than a general solution. For instance solutions were
focused on heart failure [155], HIV [156], diabetes [157], and kidney transplants [158]. Second, no
model has been able to predict ICU readmissions to a satisfactory degree yet [159]; most models
suffer from a low sensitivity of around 0.6 to 0.65 [145, 153, 159]. Third, most models do not utilize
the sequential data structure and time series feature of many EHR parameters which can lead to
information loss [160]. Last, very few attempts to understand and interpret the predictive model.
Feature interpretation, as well as decision making logic, reliability, and robustness analysis of the
machine learning models is crucial, and more imperative for clinical applications. This task is much
more complex for deep learning techniques, which has made recent works short of explaining the
decision making logic and model interpretation [161, 162].
In this study, we focus on the analysis and prediction of unplanned ICU readmission using recent
deep learning techniques and utilizing time series feature of data. We propose a recurrent neural
network (RNN) architecture with long short-term memory (LSTM) layers to enhance the predictive
model by incorporating the time series data. We also incorporate low-dimensional representations
(also called embeddings) of medical concepts (e.g. diseases ICD-9 code, treatment procedure, and
laboratory tests) as the input of our model [150, 163]. Finally, we test, validate, and explain
the proposed methods using the MIMIC-III dataset [164], containing more than 40,000 patients’
information and 60,000 ICU admission records, over a 10 year period [164]. We leverage this
extensive dataset to develop predictive model which provides clinicians with the much needed
decision-making support. This data-driven approach can help prevent the inappropriate discharge
or transfer of patients at high-risk of ICU readmission along with reducing the associated costs and
penalties.
5.2 METHODS
To accompany this report, and to allow independent replication and extension of our work, we
have made the code publicly available under GPLv3 for use by non-profit academic researchers
at https://github.com/Jeffreylin0925/MIMIC-III_ICU_Readmission_Analysis. The code is
part of the supplemental information; it includes the step-by-step instructions of the statistical and
machine learning analysis.
5.2.1 Dataset construction
The readmission dataset is constructed from the MIMIC-III Critical Care Database. MIMIC-III
consists of the health-related EHR data of more than 40,000 patients in the Intensive Care Units
(ICU) of the Beth Israel Deaconess Medical Center between 2001 and 2012. One patient may have
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multiple in-hospital records in the dataset. Following the data screening process stated in [157], we
first screen out the patients under age 18 and remove the patients who died in the ICU. This results
in total number of 35,334 patients with 48,393 ICU stays. We then split the processed patients into
training (80%), validation (10%), and testing (10%) partitions to train our model and conduct a
five-fold cross-validation. Note that one patient may have multiple records, so the number of items
may not equal in each fold.
To construct the dataset for ICU readmission, we categorize all selected patients and their
corresponding ICU stays records into positive or negative cases. Specifically, the following cases
are considered to be positive patient stays:
• 3,555 records: the patients were transferred to low-level wards from ICU, but returned to
ICU again,
• 1,974 records: the patients were transferred to low-level wards from ICU, and died later,
• 3,205 records: the patients were discharged, but returned to the ICU within the next 30
days,
• 2,556 records: the patients were discharged and died within the next 30 days.
Positive cases are regarded as the ones where the patients could benefit from a prediction of
readmission before being transferred or discharged. Negative cases, on the contrast, are those
where the patient does not need ICU readmission. Specifically, patients who were transferred or
discharged from ICU and did not return and are still alive within the next 30 days are considered
to be negative cases.
5.2.2 Feature extraction
In this section, we introduce the features and the time series window we use for the ICU read-
mission prediction task. For temporal information modeling of the time series ICU records, we
use the last 48-hour data of each ICU stay. The last 48 hours before the patient is discharged
or transferred are found to be the most informative data for prediction of readmission [165, 166].
To cope with the problem of data missingness, we use Last-Observation-Carried-Forward (LOCF)
imputation method. In cases where the last hour is missing, we include an indicator for missingness.
We use three categories of features for developing our readmission prediction model, namely
chart events, ICD-9 embeddings, and demographic information of the patients. First, chart events
category, which are extracted from health care provider (e.g., physicians and nurses) notes. Chart
events represent the patient’s’ physiological conditions based on the experts’ observation and opin-
ions [159]. Second, patient variables like chronic diseases. This category has been found to strongly
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Table 5.1: 17 Types of features in the chart events.
Chart Events Dim Normal
1. Glasgow coma scale eye opening 8 4 Spontaneously
2. Glasgow coma scale verbal response 12 5 Oriented
3. Glasgow coma scale motor response 12 6 Obeys Commands
4. Glasgow coma scale total 13 15
5. Capillary refill rate 2 Normal <3 secs
6. Diastolic blood pressure 1 70
7. Systolic blood pressure 1 105
8. Mean blood pressure 1 87.5
9. Heart Rate 1 80
10. Glucose 1 85
11. Fraction inspired oxygen 1 0.21
12. Oxygen saturation 1 97.5
13. Respiratory rate 1 15
14. Body Temperature 1 37
15. pH 1 7.4
16. Weight 1 80.7
17. Height 1 168.8
associate with ICU readmission risk [145, 165]. Third, basic demographic information, such as gen-
der, age, race. This category has also been demonstrated as important factors in the readmission
prediction [153]. In this study, we leverage all of the above-mentioned feature categories and
their time series information for the readmission prediction task. We also extract both basic and
advanced statistical features from the chart events in order to compare our proposed model to
traditional methods as baseline such as logistic regression.
Chart events: We extract 17 types of time series features from chart events within a 48-hour
window. The raw features include both numerical (e.g., diastolic blood pressure) and categorical
items (e.g., capillary refill rate). Details of these 17 features and their dimensions are shown in
Table 5.1, along with their normal median value in the humans. We use the normal values later
in the discussion section for machine learning model interpretation. In total 59 dimensions are
constructed from the chart events; the increased number is due to the one-hot encoding of the
categorical features. To identify and overcome the missing records in the chart events, we create
a 17-dim binary indicator feature, appended to the chart events feature. This feature indicates
whether the record for each type of chart event exists.
ICD-9 embeddings: Chronic diseases are found as one of the most important factors associated
with later readmissions [165]. However, this information tends to be sparse in an EHR dataset,
making them one of the most challenging to analyze with machine learning methods. In order to
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Table 5.2: Demographic Features.
Chart Events Dimension Option
1. Gender 2 Male/Female
2. Age 1 18-120
3. Insurance Type 5 Government, Self, Medicare, Private, Medicaid
4. Race 6 Asian, Black, Hispanic, White, Other, No Information
address the data sparsity of disease information in the EHR, we apply the approach presented in
[150] to compute a pre-trained 300-dimension embedding for each ICD-9 code recorded. Utilizing
a lower dimension embedding of ICD-9 benefits the model training process by avoiding a sparse
representation and applying the relationship information among different diseases. For a patient
with multiple diseases, we simply take the addition of embeddings of all the diseases in order to
construct the feature.
Demographic features: The demographic features consist of the patient’s gender, age, race, and
insurance type. Details of this category and its corresponding dimensions are summarized in Table
5.2. We include the insurance type as it could potentially influence the discharge/transfer rate.
For example, although unlikely, an insurance type uninsured could lead to insufficient payment
and might result in an unexpected discharge. In total there are 14 dimensions for the demographic
category.
Statistical features for baseline models: For the purpose of comparison to the traditional meth-
ods, we also extract the statistical features within each 48-hour window. We include the slopes
and intercepts of the regression line (a and b in y = ax+ b) as separate features to characterize the
linear trend for continuous data including the numerical chart events. Linear regression approach
has been widely used in ICU readmission prediction [167, 168, 169]. For the categorical data such
as capillary refill rate, we follow the approach in [170, 171] to extract the mean and majority value
over the total time period after transforming categorical events into binary or ordinal. Figure
5.1 shows an example of extracted statistical features for the baseline model comparison. After
computing the statistical features, each 48-hour data window will become one single data point,
resulting in 71 dimensions of chart events.
Furthermore, in order to include chart events’ volatility, we include more complex statistical
features to enhance the regression model for better baseline model comparison. For numerical
data, we extract: (i) quadratic term, (ii) standard deviation, (iii) mean absolute deviation, and
(iv) R2. Adding these statistical features, results in the increase of dimensions from 2 to 6 for
numerical features. For categorical data, we extract: (i) majority value, and (ii) how often the
value switches. These statistical features enable us to better capture the volatile nature of ICU
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Figure 5.1: Statistical feature computation. For numerical chart events, we conduct linear
regression on the 48-hour data points and record the rate and bias value as the feature. For
categorical events, we simply compute the average occurrence of the categories.
events in the traditional baseline models. We call the earlier statistics “basic statistical features (B-
STAT)” and the combination of basic and more complex statistical features “advanced statistical
features (A STAT)” for the rest of this paper.
5.2.3 Machine learning model structure
Baseline models: The first baseline model that we include is the logistic regression models. In
this study, we implement logistic regression with both L1 and L2 regularization penalty. We further
train three conventional machine learning models as our baseline, including Naive Bayes, Random
Forest, and Support Vector Machines (SVM).
Convolutional neural network (CNN) model: We also implement a CNN-based model for com-
parison to our LSTM model. CNN-based models are found useful in analyzing longitudinal EHR
data [161]. Shown in Figure 5.2, we use a multi-filter CNN structure introduced in [172]. We use
the CNN model on a comprehensive and longitudinal representation of data with 18,720 dimensions
as shown in Figure 5.3. We conduct the convolution on the time axis with 48-hour time window
and D dimension using filter size 2, 3 or 4 accordingly. The computed feature maps are finally
concatenated and fully connected to a dense decision layer with one output neuron.
Long short-term memory (LSTM) model: LSTM networks are found well-suited to making
predictions based on time series data, especially for clinical measurements where there can be lags
of unknown duration and missing values in a time series [173]. Figure 5.4 shows our utilized LSTM
model. We use a bidirectional LSTM combined with an additional LSTM layer, followed by a dense
decision layer with one output neuron activated by a sigmoid function. Overall, we have 16 hidden
units in our LSTM layer. Bidirectional LSTM learns the temporal information across the whole
training window. Considering an ICU stay record with a length of 48 hours, observation at each
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Figure 5.2: The 1D multi-filter convolutional neural network. We conduct the convolution
on the time axis with 48-hour time window and D dimension using filter size 2, 3 or 4
accordingly. The computed feature maps are finally concatenated and fully connected to a
dense decision layer with one output neuron.
hour is denoted by xt ∈ R1×D, where t is an integer from 1 to 48, and D is the feature dimension
size. The output of a single LSTM cell can be computed by the following equations,
it = σ(W.[ht−1, xt] + bi)
ft = σ(Wf .[ht−1, xt] + bf )
Ĉt = tanh(Wc.[ht−1, xt] + bc)
Ct = ft  Ct−1 + it  Ĉt
ot = σ(Wo.[ht−1, xt] + bo)
ht = ot  tanh(Ct)
(5.1)
The above functions can be simply denoted by ht = LSTM(ht−1;xt). We utilize the hidden
value of the last time stamp to predict the readmission possibility, thus the final output after going
through the dense layer would be,
rT = σ(Wr.h48 + br) (5.2)
where σ is the indicator of the sigmoid activation function, and the rT represents the prediction
probability of whether this patient with the ICU stay record will be readmitted, ranging from zero
to one. The dimension of ht is R1×16, therefore the Wr ∈ R16×1. We also use binary cross entropy
loss to update the weights. In addition to separate CNN and LSTM based models, we also imple-
ment and compare the performance of the LSTM and CNN combination models. We implemented
all the models using Keras based on the benchmark code of [160]. The learning rate of training
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Figure 5.3: The data structure of input data used with CNN and LSTM models. D: dimen-
sion, h: hour.
was set to 1e-3, and we used Adam optimizer to train the model with beta 0.9. We trained at most
50 epochs and selected the model with the highest AUC on the validation partition following the
logic in [173]. During the evaluation, we set up the decision threshold as 0.5.
We evaluate the performance of the predictive models by performing a five-fold cross-validation
and measuring the area under the receiver operating curve (AUC) generated by plotting sensitivity
vs (1 − specificity). We use cross-validation for detecting and preventing possible overfitting or
selection bias. We randomly divided the dataset into five subsamples, retained a single subsample
as the validation data for testing the model, and the remaining four samples used as training data.
We repeated the process five times (the folds), with each of the subsamples used exactly once as
the validation data. Performance of the model in each fold was measured and then results from all
five folds were averaged to produce a single estimation for the model’s performance.
AUC measures the overall performance of the recall with respect to different false positive rate.
Models with higher AUC will demonstrate a more powerful screening capability in assisting the
physicians. In order to further evaluate the machine learning models for a clinical setting, we
assess the AUC along with operating points corresponding to high-sensitivity (true positive rate)
and high-specificity (true negative rate) of the algorithm with respect to the reference standard
[174, 175, 176, 177, 178]. Targeted operating points are used for different clinical purposes, for
instance high-sensitivity is targeted for ruling out the disease, whereas high-specificity is used for
ruling in the disease [179]. In this study, in order to evaluate the performance under consistent
conditions, the operating points correspond to fixed sensitivity and specificity at 0.80 and 0.85
[174, 176, 177]. In practice, high-sensitivity (or recall rate of positive cases) plays a more important
role in screening the patients. In essence, a highly sensitive test indicates that the model can
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Figure 5.4: LSTM model. A bidirectional LSTM combined with an additional LSTM layer,
followed by a dense decision layer with one output neuron activated by a sigmoid function.
Overall, we have 16 hidden units in our LSTM layer.
correctly identify patients with a high risk of readmission in a critical department such as ICU.
5.3 RESULTS
In this section, we illustrate the experiments we conducted to evaluate the performance of the
predictive models. We evaluate the conventional models (logistic regression, random forest, Naive
Bayes, and SVM), as well as, the deep learning based CNN and temporal LSTM models. We
compare and obtain the optimal ICU readmission prediction solution.
5.3.1 Baseline models
We first evaluate logistic regression models with both L1 and L2 regularization penalty. Results
are shown in Table 5.3 part (a) under “Baseline-Regression”. We first observe that using logistic
regression with L2 regularization on the advanced statistical features (A STAT) can slightly im-
prove the AUC performance compared to the basic statistical features (B STAT), 0.770 (95% CI,
0.758-0.782) to an AUC of 0.771 (95% CI, 0.759-0.783). However, we do not observe any AUC
improvement for the logistic regression with L1 regularization by having more advanced statistical
features (stays at AUC of 0.775 (95% CI, 0.765-0.786)). In addition to advanced statistical features,
the demographic features can also slightly improve the performance from an AUC of 0.771 (95%
CI, 0.759-0.783) to an AUC of 0.773 (95% CI, 0.762-0.787) using the logistic regression with L2
regularization.
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Table 5.3: Performance comparison of various machine learning models on different sets of features.
Acc: Accuracy. Pre: Precision. Re: Recall. A.R: AUC under ROC. A.P: AUC under PRC. L48:
Last 48 hours. F48: First 48 hours. CE: Chart Events. D: Demographic features. C.I.: 95%
confidence interval. B STAT (basic statistical features): slope and intercept. A STAT (advanced
statistical features): B STAT plus continues and categorical features including quadratic term,
standard deviation, mean absolute deviation, R2, Majority value, value change frequency.
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End of Table 5.3
Overall, we see that the prediction accuracy can be slightly improved by adding more complex
statistical features as well as demographic ones. The best performing logistic regression model is
with L1 regularization on A STAT combined with the demographic features, AUC of 0.777 (95%
CI, 0.765-0.789) and sensitivity of 0.680 (95% CI, 0.662-0.697). Furthermore, we trained three
conventional machine learning models as our baseline, including Naive Bayes, Random Forest,
and SVM on both B STAT and A STAT features. The results are shown in Table 5.3, part (b),
“Baseline-Conventional Machine Learning”. SVM outperforms other traditional methods by reach-
ing an AUC of 0.779 (95% CI, 0.768-0.789) with A STAT, which is a negligible increase from an
AUC of 0.775 (95% CI, 0.765-0.785) with B STAT.
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5.3.2 CNN and LSTM models
We first conduct a feature ablation study to evaluate the effect of various feature selections on
the system’s performance. Then, we attempt multiple model structures including bidirectional
LSTM, CNN, and the combinations of both.
Feature selection: We select the Bidirectional LSTM as our base model and deploy different
combinations of feature inputs. As shown in Table 5.3 part (c), our results demonstrate that the
last-48h features perform relatively better than the first-48h data in terms of positive recall rate
and AUC. In addition, ICD-9 embedding is necessary for predicting the readmission rate. We also
observe that the demographic features greatly benefit the performance. Overall, the full set of
features including Last-48h chart events and their identifiers, ICD-9 embeddings, and demographic
information perform the best among all the combinations.
Model selection: We attempted multiple model structures including bidirectional LSTM, CNN,
and the combinations of both. Figure 5.5 shows our strategy for combining the bidirectional LSTM
and CNN models. We use the 1D multi-filter CNN model introduced in the previous section. As for
the CNN+LSTM model, the CNN follows a multi-filter convolution computation with zero padding
to maintain the timestamp consistency for different groups of feature maps. The following LSTM
only outputs the hidden units of the last time stamp. However, for the LSTM+CNN model, CNN
computes the feature maps without zero padding after receiving the output hidden unit sequence
from LSTM. As shown in Table 5.3 part (d), our experimental results reveal that LSTM followed
by a CNN, utilizing all the feature sets, obtains a higher positive recall rate and overall predic-
tion performance. The proposed model outperforms the conventional machine learning approaches
trained on both basic and advanced statistical features. The ROC curve for some of the selected
high performing machine learning models are shown in Figure 5.6.
To further demonstrate the ability of deep learning model in the readmission prediction, we look
at the operating points corresponding to high-sensitivity (true positive rate) and high-specificity
(true negative rate) of the algorithm. Table 5.4 summarizes the performance of the algorithms.
Using the operating cut point with high specificity of 0.85 and 0.8, we observe that LSTM+CNN
results in the highest sensitivities of 0.548 (95% CI, 0.522-0.575) and 0.619 (95% CI, 0.597-0.642)
respectively, a significant improvement from the best baseline. Evidently, even the basic LSTM
model outperforms the best baseline, regression with L1 regularization, by improving the sen-
sitivities from 0.525 (95% CI, 0.505-0.546) to 0.540 (95% CI, 0.503-0.577) and 0.596 (95% CI,
0.575-0.618) to 0.611 (95% CI, 0.573-0.649) respectively.
We then evaluated a second operating point for the algorithm, with a high-sensitivity, reflecting
an output that would be used for a screening tool. Using this operating point, LSTM+CNN had
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Figure 5.5: Combination of LSTM and CNN models. (a) CNN+LSTM model, the CNN
follows a multi-filter convolution computation with zero padding to maintain the timestamp
consistency for different groups of feature maps. The following LSTM only outputs the
hidden units of the last time stamp. (b) LSTM+CNN model, CNN computes the feature
maps without zero padding after receiving the output hidden unit sequence from LSTM.
sensitivities of 0.85 and 0.8 and the highest specificities of 0.537 (95% CI, 0.515-0.559) and 0.618
(95% CI, 0.593-0.643), again an improvement from conventional machine learning models.
5.4 DISCUSSION
In this section, we dive deeper into our machine learning model in an effort to further interpret
the results, its capabilities, and limitations. We perform ablation study to investigate the most
important factors that the deep learning model has learned in order to predict the ICU readmission.
Then, we review the clinical literature for additional verification and a better clinical understanding
of the deep learning model. Finally, we examine the advantages and strength of the proposed model
over traditional machine learning models. We look at the characteristics and statistics for the true
positive sets of each model.
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Figure 5.6: ROC curve of selected high performing machine learning models. The color
bar is the error bar of the ROC curve with five-fold cross-validation. LSTM-CNN model
performs relatively better than other ones. CE: chart events. D: Demographic features.
5.4.1 Model interpretation: Feature ablation test
We conducted the feature ablation test on the chart events to better understand the underlying
logic of our proposed model. We selected all the positive cases from the testing partition. Then
we obtained all the true positive samples through running the LSTM+CNN model utilizing all the
features. These true positive cases are the ones recalled correctly by our proposed model. For each
case, we iterated over all the chart events, each time, changing only one event to its normal value
in the humans. We recorded the number of cases that were falsely predicted due to the change.
Then we ranked all the chart events according to the change numbers. Figure 5.7 shows the results
of feature ablation test based on the changing ratio of the prediction results after we replace the
original feature with its normal value. We see that Glucose is the most important factor learned by
the deep learning model for the readmission prediction task, while Capillary Refill Rate, Fraction
inspired Oxygen, and Systolic Blood Pressure do not have significant influence on the prediction
results. However, the performance change of the predictive model is not dramatic. We believe
this may be due to possible biological and clinical correlation among different factors. This can be
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further evaluated by the back-propagation approach in future work.
5.4.2 Model interpretation: Features in line with the clinical literature
Furthermore, we review the clinical literature for additional verification and a better understand-
ing of the deep learning model system. The results of the feature ablation test from the previous
section point out that abnormal Glucose, Heart Rate, Body Temperature, Glasgow Coma Scale,
and Oxygen Saturation are the top five important features in predicting unplanned readmission in
the ICU. Interestingly, the underlying deep learning logic and its findings are in line with the exist-
ing clinical literature. Prior research has found that the presence of comorbidities, such as diabetes,
heart failure, renal failure, and pneumonia, are the main risk factors resulting in unplanned read-
missions [180, 181]. These disorders are shown to have strong correlations with abnormal features
identified by our model [157]. Moreover, several studies have worked on the readmission problem
by only focusing on the aforementioned conditions.
For instance, many researchers have focused on hospitalization and unplanned readmissions by
looking at the abnormal Glucose status. Berry et al discovered the significant positive relationship
between levels of admission blood glucose and risk of readmission for patients with heart failure
[182]. Evans et al identified that the glucose level on admission performs as a prognostic predictive
factor for early readmission rates, even for those with diabetes [183]. Dungan has demonstrated
that higher time-weighted mean glucose is associated with the increase of congestive heart fail-
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Figure 5.7: The results of feature ablation test. The importance of chart events for predicting
the ICU readmission. The y-axis shows the changing ratio of the prediction results after we
replace the original feature with its normal value.
ure (CHF) readmission [184]. Emons et al focused on hypoglycemia-related readmission issue and
expose the linear relationship between blood glucose level closest to discharge and the risk of hy-
poglycemic readmission [185].
Heart failure is another main risk factor resulting in early readmission [186]. Heart failure indi-
cates that the cardiac muscle cannot pump the blood properly. This behavior is strongly reflected
through abnormal heart rate [187, 188]. Keenan et al developed a hierarchical logistic regression
model to predict readmission for those patients hospitalized with heart failure issues [187]. Hammill
et al utilize heart rate record during hospitalization as one of the main features to predict 30-day
outcomes after heart failure hospitalization [188].
In addition, patients with renal failure are suggested to be among the highest risk patients with
30-day readmission [189]. Previous studies have shown that body temperature is a vital determi-
nant of ischemic renal injury [190]. Moreover, Sood et al found that body temperature and Glasgow
coma scale are two significant features to predict early ICU readmission for patients with end-stage
renal disease (ESRD) [191].
Last but not least, a study has revealed that around 140,000 hospital readmissions per year
are owing to pneumonia [192]. Halm et al apply a regression to examine the relationship between
patients’ instabilities and the risk of early readmission. They proposed a list of unstable factors
leading to higher risk of 30-day hospital readmission, including (temperature >37.8°C, heart rate
>100 bpm, respiratory rate >24/min, systolic blood pressure <90 mmHg, oxygen saturation <90%,
inability to maintain oral intake, and abnormal mental status) [193].
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In summary, the underlying logic of our deep learning model, as well as the most important
features identified by the model, are in line with the existing clinical literature.
5.4.3 Strengths of the model
To better understand the advantages and strength of the LSTM-based model over the traditional
models, we investigate the positive patients correctly predicted by the LSTM+CNN but misclassi-
fied by the logistic regression with L1 regularization. Overall, there are 441 positive patients, across
all the testing partition folds, who are correctly predicted only by the LSTM+CNN model and not
the logistic regression. We refer to these 441 patients as LSTM-C set. Meanwhile, 3,068 cases are
correctly predicted by both the LSTM+CNN and Logistic Regression with L1 regularization. We
refer to these 3,068 cases as LSTM-LR-C set.
LSTM-based models are found to provide a robust prediction for time series with notable fluc-
tuations in the data [194]. We verify this phenomenon by measuring the degree of value oscillation
for LSTM-C and LSTM-LR-C, and also looking at individual cases. We introduce Dnm, measuring
the degree of oscillation for record n of chart event m. Given a numerical chart event sequence






|xt − xt−1| (5.3)
where T is equal to the length of a record, normally 48, if there is no missing data.
Using Dnm as a measure for the degree of oscillation, we compute the highest oscillation for each
stay across all the 12 numerical chart events and compare their statistical distributions in LSTM-C
and LSTM-LR-C. We first estimate Pm, the cumulative density function (CDF) of each chart event
on the whole positive set. Then we remapped each Dnm to the probability pnm, and computed the






where wn represents the highest oscillation among all the chart events for this record.
Finally, for both LSTM-C and LSTM-LR-C sets, we plotted the CDFs of the estimated his-
tograms of wn in Figure 5.8. We can see that there are more patient records in the LSTM-C which
have at least one chart event with high oscillation sequence. Essentially, compared to Logistic
Regression, our LSTM+CNN model is capable of capturing high volatile time series behavior, a
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common pattern in high-risk ICU patients.
Figure 5.8: Cumulative density function curve of LSTM-LR-C (red line) and LSTM-C (blue
line). Figure shows that there are more patient records in the LSTM-C which have at least
one chart event with high oscillation sequence. Essentially, compared to Logistic Regression,
our LSTM+CNN model is capable of capturing high volatile time series behavior, a common
pattern in high-risk ICU patients.
To further study the strength of our LSTM+CNN solution, we look at individual cases. For
each chart event, we selected the patients with the highest Dnm in the LSTM-C and plotted the
sequence values of their stay. Figure 5.9 illustrates two of these patients. Both patients have high
volatile chart events. However, in both cases the abnormal sequence has oscillated around the
normal value of the chart event, which in return a linear model would regress it to a normal value
with a negligible slope. Effectively, a linear model would lose a very important factor in predicting
the readmission: repeated illness and unstable status.
We further investigate the strength and weaknesses of the LSTM-based model by looking at
the oscillation issue among all the chart events. We investigate the differences between positive
patients who are predicted correctly only by the logistic regression with L1 regularization and those
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Figure 5.9: (a) A selected ICU stay with the highest heart rate event oscillation, and (b)
another case with the highest oscillation of respiration rate. These two patients are predicted
correctly by the LSTM-CNN model, but wrongly by the traditional models. In both cases,
the abnormal sequence has oscillated around the normal value of the chart event, which in
return a linear model would regress it to a normal value with a negligible slope. Effectively,
our LSTM-CNN is capable of capturing such high volatile behavior, a common pattern
among high-risk ICU patients with unstable status.
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Table 5.5: KolmogorovSmirnov (K-S) test for the distribution of fluctuation between LSTM-
C and LR-C for each chart event.
Two-sample KolmogorovSmirnov (K-S) test
D P value
Glucose 0.1519 0.012
Heart rate 0.0635 0.766
Temperature 0.0839 0.42
Oxygen saturation 0.1678 0.004
Diastolic blood pressure 0.0794 0.491
Respiratory rate 0.102 0.201




Fraction inspired oxygen 0.0499 0.947
Systolic blood pressure 0.0635 0.766
who are predicted correctly only by the LSTM+CNN. As mentioned earlier, there are 441 positive
patients who are predicted correctly only by the LSTM+CNN model, denoted as the LSTM-C set.
On the other hand, there are 147 cases that are predicted correctly only by the logistic regression
with L1 regularization, we denote this set by LR-C.
Our goal is to identify the differentiating factors between the LR-C set and the LSTM-C. We
analyze the fluctuation distribution for each chart event in both sets. We use the Eq 5.3 to calculate
the Dnm, measuring the degree of oscillation for chart event m of patient n. We then estimated
the cumulative density function (CDF) of each chart event in each set. For each chart event, we
conduct KolmogorovSmirnov test (K-S test) on factor Dnm to compare the distributions of this
factor between the two sets. The results are shown in Table 5.5.
Results reveal that patients in the LR-C tend to have a higher probability of achieving lower
scores of factors Dnm on “Glucose” than patients in the LSTM-C (maximal absolute difference
between the distribution functions (D) = 0.1519, p-value = 0.012). In addition, we also observe
that patients in the LR-C set tend to have a higher probability of achieving lower scores of factors
Dnm on “Oxygen Saturation” than patients in LSTM-C (D = 0.1678, p-value = 0.004). The CDF
of “Glucose” and “Oxygen Saturation” are shown in Figure 5.10 part (a) and (b). We further use
the Probability density function (PDF) plots of both features to show this phenomenon in Figure
5.10 part(c) and (d). The results in this section further enhance the suggestion that deep learning
has advantages over logistic regression in predicting datasets with large fluctuation of time series
features, “Glucose” and “Oxygen Saturation” in this case.
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Figure 5.10: Cumulative density function (CDF) plots and probability density function
(PDF) plots.
5.4.4 Comparison with the baseline models
In addition to comparing LSTM-based model and logistic regression with L1 regularization, we
further compare LSTM-based model with all the six baseline regression models, including: (i) L1
logistic regression with B-STAT, (ii) L1 logistic regression with A STAT, (iii) L1 logistic regression
with A STAT and Demographic features, (iv) L2 logistic regression with B-STAT, (v) L2 logistic
regression with A STAT, and (vi) L1 logistic regression with A STAT and Demographic features.
We define LSTM-C-all as the set of positive ICU readmission cases which can only be identified
by LSTM+CNN model and not any of the six baseline regression models as mentioned above.
Overall, 201 cases are contained in LSTM-C-all.
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Table 5.6: Summary of the number of cases correctly predicted by the corresponding baseline
model as well as the LSTM+CNN.








Furthermore, we define the following sets: (i) LSTM-LR-L1-B STAT set, (ii) LSTM-LR-L1-
A STAT set, (iii) LSTM-LR-L1-A STAT-D set, (iv) LSTM-LR-L2-B STAT set, (v) LSTM-LR-L2-
A STAT set, (vi) LSTM-LR-L2-A STAT-D set as the sets that are correctly predicted by both the
LSTM+CNN and respective baseline logistic regression models. Summary of the number of cases
contained in each of these sets is shown in Table 5.6.
We follow the same logic described in the previous section, to capture the maximum probability
wn of record n for each set mentioned above. Then, we plot the CDF of wn for each set. Results
are shown in Figure 5.11. Figure shows that the CDF representing oscillation of the LSTM-C-all
set is still the lowest one. The observation is consistent with the previous observation in the section
“Strengths of the model”: there are more patient records in the LSTM-C-all which have at least
one chart event with high oscillation sequence. The result enhances our argument that compared
to baseline logistic regression models, our LSTM+CNN model is capable of capturing high volatile
time series behavior, a common pattern in high-risk ICU patients.
The rest of the CDF lines represent oscillation of the six sets predicted correctly by both the
LSTM+CNN and various logistic regressions models. We observe that the six CDFs are almost
identical. Based on this observation, we conclude that even though using A STAT (mode advanced
statistical features) can slightly enhance the performance of baseline logistic regression models (as
shown in Table 5.3), it can hardly improve the ability of logistic regressions to capture the critical
oscillations in ICU patients. The results further enhance the advantage of using LSTM based model
to identify patients with a high risk of readmission in a critical department such as ICU.
5.5 SUMMARY
In this study, we addressed the unplanned ICU readmission prediction by utilizing chart events,
demographics and ICD-9 embeddings features. Among the data that we used, chart event features
are significantly sensitive to time series, and cannot be properly captured by conventional machine
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Figure 5.11: CDF plots of wn for sets in Table 5.6.
learning models (e.g., logistic regression). After in-depth analysis of ICU data, it turned out that
sudden fluctuations in chart event features (e.g. glucose and heart rate) are strong signals of pa-
tients volatile status. We propose a LSTM-CNN based model, which can properly incorporate time
series data without information lost.
Our machine learning solution for prediction ICU readmission offers higher accuracy and sensitiv-
ity compared to existing solution. In addition, since the model can have multiple operating points,
its sensitivity and specificity can be tuned to match requirements for specific clinical settings, such
as high sensitivity for critical care. In this study, AUC of 0.791 and sensitivity of 0.742 were
achieved. Moreover, we illustrated the importance of each input features and their combinations in
the predictive model This fast and interpretable solution holds the potential for substantial clinical
impact by augmenting clinical decision-making for ICU specialists. Further research is necessary
to evaluate performance in a real-world, clinical setting, in order to validate this technique across
varying critical care practices.
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CHAPTER 6: CONCLUSIONS
6.1 SUMMARY OF CONTRIBUTIONS
In summary, this work used machine learning techniques to enable the construction of the human
aging model. Descriptive, predictive, prescriptive machine learning methods contributed to the hu-
man aging model and permitted health-related decisions for clinicians and individuals. We have
taken a comprehensive and multi-disciplinary approach to the human aging model described by
three principal components: (i) healthy aging, (ii) longitudinal and multi-modal data, (iii) machine
learning and cloud computing. We focus on brain aging and neurological disorders. This subset of
aging-related disorders is representative of a large portion of aging trajectories. Our data-driven
strategy starts with the collection and integration of longitudinal studies with highly dimensional
multi-modal datasets. With longitudinal and multi-modal data in hand, we utilize machine learning
techniques including supervised, unsupervised, and semi-supervised learning to analyze the data
and develop models. Analyzing health data and particularly imaging and genomics data, pose se-
vere computational challenges. To address the storage and computational challenges posed by big
health data, we design and use cloud computing-based analytical systems that have transitioned
from shared, centralized architectures to distributed, decentralized architectures. We propose sev-
eral models for aging and neurological disorders as one of the most prominent health disorders in
our aging population. These models address Parkinson’s disease, Alzheimer’s disease, Amyotrophic
lateral sclerosis (ALS), and Intensive Care Unit (ICU). Our solutions impact the whole spectrum
of aging-related healthcare from patients and caregivers to physicians and clinicians to providers
and insurers. This work complements and supports many other researchers’ efforts in modeling
aging-related disorders.
In Chapters 2 and 3, we studied Parkinson’s and Alzheimer’s disorders, respectively. In both
chapters, we integrated unlabeled, multi-modal, and longitudinal data. The longitudinal data had
a long-term nature, and we were interested in capturing the overall pattern of the individual’s
trajectories. Vectorization and NMF methods were the most successful approach for extracting
long-term trajectories. Using comprehensive multi-modal data helped us develop an embedded
space. This space was crucial for understanding the trajectories and dimensions in which the
individuals traverse. Having this easily interpretable space, we were able to use GMM unsuper-
vised learning approach to identify new subtypes of the disorder based on disease progression.
We also provided an in-depth analysis of these subtypes. Furthermore, we developed predictive
models for early diagnosis, prognosis, and clinical trial stratification. Significant effort was also
put into the interpretation of the predictive models. Predicting progression rates would lead to
better patient-specific attention by recognizing at an early stage the patients with a swift rate
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of progression. The proposed disease progression and trajectory prediction algorithms can help
doctors and practitioners develop a methodical and organized course for clinical tests, which can
be much more concise and effective in detection. These adaptations and modifications in clinics
may help to diminish treatment and therapy costs for aging disorders. Further, the capability to
anticipate the trajectory of impending Alzheimer’s and Parkinson’s progression at the early stages
of the disease is an advancement towards uncovering novel treatments for disease modification. The
proposed analysis provides insights to inhibit or decelerate the progression of aging-related symp-
toms and subsequent deterioration in the characteristics of life that are accompanied by the disease.
In Chapter 4, we introduced our work on Amyotrophic lateral sclerosis (ALS) disorder. Similar to
Alzheimer’s and Parkinson’s chapters, we used an unsupervised learning approach to identify new
subtypes. However, unlike Parkinson’s and Alzheimer’s, which have a long multi-year course, we
do not predict progression. Since ALS is a rapidly progressive disorder, we focus on subtype iden-
tification and survival analysis. To enhance our ability to resolve the different types of spinal-onset
ALS, we used semi-supervised learning. We incorporated the physician’s assessment of patients for
the predictive task. With the trained model, we dissected the machine learning model to realize
the underlying ALS structure which machine has learned. This representation is a close proxy
to what the model learned about data for it to classify patients as observed by the physician a
year into the disease – resulting in a more fine-tuned representation of ALS subtypes compared to
the fully unsupervised. Notably, the machine learning combined with the physician’s observations
arrived at a more fine-tuned conclusion, highlighting the importance of augmentation (and not
a replacement) of the machine with clinicians. In order to ensure the generalizability and valid-
ity of the results, we replicate the ALS subtype identification in the independent replication cohort.
In Chapter 5, we presented our work on readmission prediction in the Intensive Care Unit (ICU).
Unlike previous chapters where the health issue has a multi-year course, in the ICU, data is short-
term. Short-term data such as sensory and monitoring device data has a high frequency of data
collection, but with a time window of hours to days. Due to the data collection frequency, different
predictive machine learning methods are used to encapsulate the time-sensitivity of small fluctu-
ations in the patient’s status. After an in-depth analysis of ICU data, it turned out that sudden
fluctuations in chart event features (e.g., glucose and heart rate) are strong signals of patients’
volatile status. Comparing various methods, we show that our LSTM-based solution can better
capture high volatility and unstable status in ICU patients, an important factor in ICU readmission.
This work highlights the ability of machine learning models to improve our ICU decision-making
accuracy and is a real-world example of precision medicine in hospitals. Due to human limitations,
many behavioral changes and sudden fluctuations are most often missed. Moreover, we illustrated
the importance of each input features and their combinations in the predictive model. This fast
and interpretable solution holds the potential for substantial clinical impact by augmenting clinical
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decision-making for ICU specialists.
The models and solutions developed in this dissertation are designed for different scenarios, but
share the following designing principles:
i Lack of data for supervised learning. In order to develop accurate predictive models based
on supervised learning, we need large and reliable data. In healthcare, such data is mostly
not available; labels come from physicians who themselves have a high misdiagnosis rate.
To overcome this challenge, this work heavily relies on labeling data using unsupervised and
semi-supervised learning techniques.
ii Utilization of short-term and long-term longitudinal data. In order to develop a timely model
of aging, we need to incorporate longitudinal studies with time-series data. In healthcare,
we have both short-term and long-term longitudinal data. Short-term data such as sensory
and monitoring device data has a high frequency of data collection, but with a time window
of hours to days. On the other hand, long-term data such as clinical assessments have a low
frequency of data collection with a time window of six months to two years. In this work,
we utilize both types of longitudinal data.
iii Integration of multi-modal data. Many machine learning techniques focus on one type of data,
e.g., only imaging or audio. However, in healthcare, we look at the human body from different
modalities, and we hope by integrating all of them, we can have a better understanding of
the issue. Utilizing highly dimensional multi-modal datasets, including clinical, biological,
genetic, and imaging data have been part of this work.
iv Interpretability. Using unsupervised machine learning techniques, we have developed embed-
ding spaces that have guided us in labeling the subjects. Part of this labeling relies on our
success in interpreting the embedding spaces. In this work, we have put effort into dissecting
the machine learning “black box” to understand the results better and guide the development
of models.
We also address the following clinical challenges:
i Replication of results with other datasets. Validating findings and replication is an underpin-
ning of research. Generalizing, the same methods and protocols should be used on a different
group of people, or a different setting, and come up with similar results. In healthcare, lack
of data has made replication more sparse. However, in this work, when possible, we show
that results are valid in external datasets.
ii Developing usable models in both clinical and research settings. Models with higher accuracy
demonstrate a more powerful screening capability in assisting the physicians. However, accu-
racy is not enough, and we need to further evaluate the machine learning models for use in a
96
clinical setting. We need to assess the accuracy along with operating points corresponding to
sensitivity (also called the true positive rate, the recall, or probability of detection) and speci-
ficity (true negative rate) of the algorithm with respect to the reference standards [61]. It is
often claimed that these targeted operating points can be used for different clinical purposes;
for instance, a highly sensitive test is deemed effective at ruling out a disease when negative,
whereas a highly specific test is effective at ruling in a disease when positive. However, these
rules are misleading, as the diagnostic power of any test is determined by both its sensitivity
and its specificity [62]. The tradeoff between specificity and sensitivity is explored in ROC
analysis [63]. In this work, we analyze the usability of all the models for clinical settings, not
only the individual operation points but across a range of values for the ability to predict a
dichotomous outcome.
iii Tangible improvement to physician’s decision making. Feature interpretation, as well as
decision making logic, reliability, and robustness analysis of the machine learning models, is
crucial and imperative for clinical applications. This task is much more complicated for recent
techniques. Many recent efforts are short of explaining the decision-making logic and model
interpretation in healthcare. In this work, we dive deeper into our machine learning model
in an effort to further interpret the results, capabilities, and limitations. We investigate the
most important factors that the machine learning model has learned in order to predict and
classify an event. We review the clinical literature for additional verification and a better
clinical understanding of the machine learning model. Finally, we examine the advantages
and strengths of the proposed models.
6.2 LESSONS LEARNED
Throughout doing this dissertation, we have come across many challenges that made us rethink
our approach. Some of the lessons we have learned about developing a human aging model and
making augmented health intelligent systems:
• Thinking about the user and setting: most often, when training a machine learning model, we
might have access to data modalities and features that are not easily accessible in the clinical
practice. In some instances, certain measurements might be costly or time-consuming to
collect. When designing and training the models, it is important to understand whether the
user has access to the same input data with similar quality. How they will input the data and
interact with the model. Fort instance, a PET scan might not be available to the physician,
or the MRI might not have the same power or calibration parameters as the training data.
• A closed-loop feedback system: training data is never comprehensive and detailed enough to
cover all scenarios, the human body’s complexities, or population diversities. To overcome
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that, the machine learning models need to continuously learn from the “human-in-the-loop”
as well as additional data. When the model is uncertain about the prediction, it should have
an option to receive feedback, maybe in the form of a nudge from a user, maybe falling back
to manual mode. This interactive mechanism requires measurement of uncertainty in the
prediction models, i.e., knowing what the model does not know, communicate that with the
user, and enable a feedback mechanism.
• Better data and more data: in many use cases, more data usually enhances better algorithms.
However, in healthcare, standardized and well-curated data is as important as more data.
Most health data is available through EHR systems, which tends to have high error and
subjectivity bias. Investment in standardized long-term data collection will pay off.
• Data diversity matters: demographic diversity in the age, gender, and racial/ethnic compo-
sition of data will have a major impact on healthcare disparities. For instance, sickle cell
disease is more common in people of African, African American, or Mediterranean heritage
[195]. Training a model on a population with European ancestry and using it in a hospital
with a majority of African American patients would lead to hazardous health outcomes.
• Nature is full of rare events: many disorders have a very low prevalence, which would cause
unbalanced class problems in machine learning. We should be diligent in addressing the
rarity through both broader data collection as well as analytical solutions. Throughout the
analysis, we should pay close attention to the ramifications of such rare events, making sure
training and evaluation methods are adapted accordingly.
• Data curation is often overlooked: in practice, one-third of our project’s time is spent on data
curation, one-third on model training, and the rest on evaluation and interpretation. Data
curation is often overlooked and considered as a tedious task. However, in healthcare-related
projects, data curation helps the data scientist to understand the domain knowledge better
and interact with the physicians. We often performed the curation task multiple times with
the physicians to ensure data bias, leakage, imputation, etc., are handled properly. Sometimes
data might be found inadequate due to significant missingness or data errors.
• Qualities of a strong machine learning model for healthcare: from the start, we need to
ensure that the resulting models are reproducible, usable, and interpretable by the user.
Also, generalizable to a targeted population.
• Simple models are better than complex models: a principle most widely known as Occam’s
razor, or the Law of Parsimony, states that “it is better, in explaining something, to use as
few assumptions as possible” [196]. This idea is more formalized in statistical learning theory
[197]; simply, among competing hypotheses that explain known observations equally well, one
should choose the “simplest” one. A variation used in medicine is called the “Zebra”: a doctor
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should reject an exotic medical diagnosis when a more commonplace explanation is more
likely [198]. In many healthcare use cases, interpretability and explainability of a machine
learning model are more important than complex models even if they improve accuracy by a
small percentage. For instance, in most cases, linear models can be interpreted and debugged
more easily than neural nets. We can examine the weights assigned to each feature to figure
out what (and how) is having the biggest impact in the model [199, 200].
• Sometimes more complex models are needed: often more complex models may not show
improvements with simple features. However, with more complex features, it is more likely
that we may require more complex models. Complex models are more successful with raw
data captured from natural phenomena such as multi-omics, imaging, and speech data.
• Unsupervised and semi-supervised more necessary than supervised learning: in healthcare,
most labels are collected by the physicians. The human judgment makes the data prone to
errors and subjectivity bias. By relying on unsupervised and semi-supervised, we would be
able to extract patterns and behaviors previously unknown to human.
• Evaluation of unsupervised learning is hard: still an open problem, especially in healthcare
where we try to capture patterns previously unknown to human. Real-life clinical trials is a
solution but a costly one.
• Global data sharing is crucial: considering the ethnicity and diversity complexities; the
only way to developing highly generalizable solutions for public health benefits is global
collaboration and data sharing.
• Privacy and ethics matters: obfuscation and anonymization of data is paramount to global
data collection and sharing in healthcare. Similarly, deployment of machine learning models
without ethical considerations will result in public distrust and pushback.
• Open science, code sharing, and documentation: we are facing a major reproducibility crisis
in science [201]. More than 70% of researchers have tried and failed to reproduce another
scientist’s experiments, and more than half have failed to reproduce their own experiments.
The reproducibility issue is no better in the Artificial Intelligence community. According
to one study, only 6% of the papers presented at two top AI conferences in the past few
years shared the algorithm’s code [202]. To allow independent replication and extension
of science, scientists must share their code and analytics notebooks publicly. This should
include a readable and annotated step-by-step statistical and machine learning analysis.
Many errors go unforeseen, public sharing, and review ensure that a minor data leakage
would not jeopardize the whole system.
• Domain knowledge matters: much of a healthcare project is spent on problem formalization,
interpreting the results, and evaluating their clinical impact. Computer scientists need to
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gain adequate medical and health knowledge. They also need to have close collaboration
with clinicians who are enthusiastic about data-driven and technology-based healthcare.
• Multi-disciplinary teams: from data collection to model test, and production deployment in a
clinical setting, healthcare projects should comprise of experts in machine learning, computer
systems, biostatistics, biology, medicine, ethics, and psychology. Building data science teams
and integrating them into existing clinical workflows can be difficult and time-consuming.
To maximize the accessibility and clinical impact of health data analytics, it is necessary to
build multi-disciplinary teams that both transcend boundaries and is highly inclusive.
6.3 FUTURE WORK
This work is only a step to a much larger pursuit of healthy aging. There are several open
problems and directions we will explore further in the future:
• Coordination, collaboration, communication, for larger datasets: plethora of worldwide col-
laborations are necessary to address challenges facing augmentation of the machine learning
in healthcare. The challenges include but are not limited to generalizability, diversity, scale,
standardization, and comprehensive evaluation. In the next decade, there need to be more
data collection efforts similar to the UKBiobank [203], the NIH All of Us research programs
[204] in terms of size, and International Parkinson’s Disease Genomics Consortium (IPDGC)
[205] in terms of international collaboration. Large studies address not only the generalizabil-
ity, ethnic diversity, and under-represented population, but also rare events and disorders.
• Privacy-preserving solutions: large-scale data collection for the benefit of public health is only
possible by ensuring individuals’ privacy and providing adequate protection. These solutions
will be a combination of law, policy, as well as technological solutions. As an example,
the United States Genetic Information Nondiscrimination Act (GINA) [206], passed into
law in 2008, prohibits discrimination by employers and health insurers based on genetic
testing. The European Union General Data Protection Regulation (GDPR) [207], which
became enforceable in 2018, regulates the protection of natural persons with regard to the
processing of personal data and on the free movement of such data. These laws have provided
individual protection but also difficulties for data sharing in science. Though still under
research and development, technical solutions such as Federated Learning [208] and related
decentralized approaches will help us enforce the protective policies while advancing the
scientific discoveries.
• Enhanced solutions for more data, more modalities, more longitudinal: with larger datasets
becoming available through the UKBiobank, the NIH All of Us research programs, and
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multiple international efforts, we will have new opportunities for developing more compre-
hensive and generalizable models. At the same time, we are going to face newer engineering
challenges. Instead of hundreds of individuals, we need to address millions of individual’s
multi-omics, imaging, biological, environmental, and geospatial data. With more longitudinal
data collection starting from early adulthood, we would need techniques with much higher
time-variant adaptability, which also addresses the data sparsity of longitudinal studies. We
also need to explore novel solutions for handling rare events and class-imbalance problems.
• Open science and democratization of tools: one solution to address the health disparities
and scientific reproducibility crisis is making data science tools more available and easier
to use. For instance, there is a high barrier for junior scientists and non-biostatisticians to
work on genomic data. To address this issue and making genomic and machine learning
more accessible, we have been working on an automated machine learning tool for genomics
called GenoML [209]. There is a need for more similar tools. Making these tools available
through upcoming data science platforms such as Terra [210] will revolutionize open science
in healthcare.
• Robust and extensive clinical evaluation: with more models developed by the community, we
need standardized practices for evaluating the correctness, robustness, and generalizability of
these models in clinical settings, across varying medical practices. This would require both
policy and engineering solutions necessary to evaluate the performance and adverse effects
of these solutions in the real-world.
• Interpretability and Human-Computer Interaction: as models used more and more in prac-
tice, we need to address the human interaction by making them more understandable for
physicians as well as the patients. We need to recognize, understand, and engage with these
users rigorously and systematically.
• Broadening our perspective of complex disorders: as we have learned, ALS, Alzheimer’s, and
Parkinson’s are not single entities, but rather represent a collection of syndromes. There is
a broad variability in the clinical manifestations of these complex disorders, which makes
the diagnosis, prognosis, counseling, and clinical trial design limited [44]. Instead of analyz-
ing individual disorders, we need to merge multiple disease datasets and let the data-driven
methods deconstruct the heterogeneity within multiple cohorts. This will require close col-
laboration between areas of medicine, as well as a paradigm shift in our study designs and
funding.
• Broader healthcare impact: human body is not just influenced by aging-related disorders.
Many other life events can impact the aging trajectory. Events such as a traumatic accident
or health epidemics can have a detrimental impact on aging. Expanding the models to other
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areas of healthcare other than aging-related disorders would enable us to capture causal
issues before adulthood or unrelated to aging.
• Training multi-disciplinary scientists, the CS/ML+Health taskforce: machine learning and
computer science are contributing to the clinical understanding of the detection and treat-
ment of health and aging-related disorders. However, the lack of a talented and skillful
workforce is becoming a major challenge in deploying data science in practice. According
to the LinkedIn August 2018 report, the demand for data science skills is rising across in-
dustries in the U.S. Consequently, the high demand has resulted in a countrywide shortage
of 151,717 professionals with data science skills [211]. This shortage gap is much wider in
healthcare, where talent is not only required to have data science expertise but also health-
care and biomedical knowledge and expertise. We believe that academia partnered with the
government, and the private sector needs to play a national role in training the data science
taskforce to empower analytics efforts in health and biomedical science.
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Oertel, “The rem sleep behavior disorder screening questionnairea new diagnostic instru-
ment,” Movement disorders, vol. 22, no. 16, pp. 2386–2393, 2007.
[85] M. W. Johns, “A new method for measuring daytime sleepiness: the epworth sleepiness
scale,” sleep, vol. 14, no. 6, pp. 540–545, 1991.
[86] D. D. Lee and H. S. Seung, “Learning the parts of objects by non-negative matrix factoriza-
tion,” Nature, vol. 401, no. 6755, p. 788, 1999.
[87] D. D. Lee and H. S. Seung, “Algorithms for non-negative matrix factorization,” in Advances
in neural information processing systems, 2001, pp. 556–562.
[88] G. J. McLachlan and K. E. Basford, Mixture models: Inference and applications to clustering.
M. Dekker New York, 1988, vol. 84.
[89] R. L. Prentice, “A case-cohort design for epidemiologic cohort studies and disease prevention
trials,” Biometrika, vol. 73, no. 1, pp. 1–11, 1986.
[90] G. Schwarz et al., “Estimating the dimension of a model,” The annals of statistics, vol. 6,
no. 2, pp. 461–464, 1978.
[91] L. Breiman, “Random forests,” Machine learning, vol. 45, no. 1, pp. 5–32, 2001.
[92] M. M. Corrada, R. Brookmeyer, A. Paganini-Hill, D. Berlau, and C. H. Kawas, “Demen-
tia incidence continues to increase with age in the oldest old: the 90+ study,” Annals of
neurology, vol. 67, no. 1, pp. 114–121, 2010.
[93] C. P. Ferri, M. Prince, C. Brayne, H. Brodaty, L. Fratiglioni, M. Ganguli, K. Hall,
K. Hasegawa, H. Hendrie, Y. Huang et al., “Global prevalence of dementia: a delphi consensus
study,” The lancet, vol. 366, no. 9503, pp. 2112–2117, 2005.
[94] V. L. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K. A. Ellis, O. Salvado, C. Szoeke,
S. L. Macaulay, R. Martins, P. Maruff et al., “Amyloid β deposition, neurodegeneration, and
cognitive decline in sporadic alzheimer’s disease: a prospective cohort study,” The Lancet
Neurology, vol. 12, no. 4, pp. 357–367, 2013.
[95] C. R. Jack Jr, V. J. Lowe, S. D. Weigand, H. J. Wiste, M. L. Senjem, D. S. Knopman,
M. M. Shiung, J. L. Gunter, B. F. Boeve, B. J. Kemp et al., “Serial pib and mri in normal,
mild cognitive impairment and alzheimer’s disease: implications for sequence of pathological
events in alzheimer’s disease,” Brain, vol. 132, no. 5, pp. 1355–1365, 2009.
[96] E. M. Reiman, Y. T. Quiroz, A. S. Fleisher, K. Chen, C. Velez-Pardo, M. Jimenez-Del-Rio,
A. M. Fagan, A. R. Shah, S. Alvarez, A. Arbelaez et al., “Brain imaging and fluid biomarker
analysis in young adults at genetic risk for autosomal dominant alzheimer’s disease in the
presenilin 1 e280a kindred: a case-control study,” The Lancet Neurology, vol. 11, no. 12, pp.
1048–1056, 2012.
109
[97] R. J. Bateman, C. Xiong, T. L. Benzinger, A. M. Fagan, A. Goate, N. C. Fox, D. S. Marcus,
N. J. Cairns, X. Xie, T. M. Blazey et al., “Clinical and biomarker changes in dominantly
inherited alzheimer’s disease,” New England Journal of Medicine, vol. 367, no. 9, pp. 795–804,
2012.
[98] H. Braak, D. R. Thal, E. Ghebremedhin, and K. Del Tredici, “Stages of the pathologic
process in alzheimer disease: age categories from 1 to 100 years,” Journal of Neuropathology
& Experimental Neurology, vol. 70, no. 11, pp. 960–969, 2011.
[99] Alzheimer’s Association, “2019 alzheimer’s disease facts and figures report,” 2019. [Online].
Available: https://www.alz.org/media/documents/alzheimers-facts-and-figures-2019-r.pdf
[100] Alzheimer’s Association, “Medications for memory loss,” 2019. [Online]. Available:
https://alz.org/alzheimers-dementia/treatments/medications-for-memory
[101] Alzheimer’s Association, “Treatments for alzheimer’s and dementia,” 2019. [Online].
Available: https://alz.org/alzheimers-dementia/treatments
[102] Alzheimer’s Association, “Alzheimer’s and dementia stages,” 2019. [Online]. Available:
https://alz.org/alzheimers-dementia/stages
[103] D. M. Holtzman, J. C. Morris, and A. M. Goate, “Alzheimer’s disease: the challenge of the
second century,” Science translational medicine, vol. 3, no. 77, pp. 77sr1–77sr1, 2011.
[104] P. Boyle, R. Wilson, N. Aggarwal, Y. Tang, and D. Bennett, “Mild cognitive impairment:
risk of alzheimer disease and rate of cognitive decline,” Neurology, vol. 67, no. 3, pp. 441–445,
2006.
[105] O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon, “Associa-
tion between csf biomarkers and incipient alzheimer’s disease in patients with mild cognitive
impairment: a follow-up study,” The Lancet Neurology, vol. 5, no. 3, pp. 228–234, 2006.
[106] S. A. Hassan and T. Khan, “A machine learning model to predict the onset of alzheimer dis-
ease using potential cerebrospinal fluid (csf) biomarkers,” International Journal of Advanced
Computer Science and Applications, vol. 8, no. 12, pp. 124–131, 2017.
[107] J. Moreland, T. Urhemaa, M. Van Gils, J. Lötjönen, J. Wolber, and C. J. Buckley, “Valida-
tion of prognostic biomarker scores for predicting progression of dementia in patients with
amnestic mild cognitive impairment,” Nuclear medicine communications, vol. 39, no. 4, p.
297, 2018.
[108] T. Altaf, S. M. Anwar, N. Gul, M. N. Majeed, and M. Majid, “Multi-class alzheimer’s disease
classification using image and clinical features,” Biomedical Signal Processing and Control,
vol. 43, pp. 64–74, 2018.
[109] “Alzheimer’s Disease Neuroimaging Initiative: ADNI,” 2016. [Online]. Avail-
able: http://adni.loni.usc.edu/wp-content/themes/freshnews-dev-v2/documents/clinical/
ADNI3 Protocol.pdf
[110] L. Berg, “Clinical dementia rating,” The British Journal of Psychiatry, vol. 145, no. 3, pp.
339–339, 1984.
110
[111] S. Zaidi, M. G. Kat, and J. F. de Jonghe, “Clinician and caregiver agreement on neuropsychi-
atric symptom severity: a study using the neuropsychiatric inventory–clinician rating scale
(npi-c),” International psychogeriatrics, vol. 26, no. 7, pp. 1139–1145, 2014.
[112] C. B. Dodrill, “A neuropsychological battery for epilepsy,” Epilepsia, vol. 19, no. 6, pp.
611–623, 1978.
[113] M. F. Folstein, S. E. Folstein, and P. R. McHugh, ““Mini-mental state”: a practical method
for grading the cognitive state of patients for the clinician,” Journal of psychiatric research,
vol. 12, no. 3, pp. 189–198, 1975.
[114] J. C. Allaire and M. Marsiske, “Everyday cognition: age and intellectual ability correlates.”
Psychology and aging, vol. 14, no. 4, p. 627, 1999.
[115] G. Salomon, D. N. Perkins, and T. Globerson, “Partners in cognition: Extending human
intelligence with intelligent technologies,” Educational researcher, vol. 20, no. 3, pp. 2–9,
1991.
[116] G. G. Fillenbaum and M. A. Smyer, “The development, validity, and reliability of the oars
multidimensional functional assessment questionnaire,” Journal of gerontology, vol. 36, no. 4,
pp. 428–434, 1981.
[117] W. J. Strittmatter, K. H. Weisgraber, D. Y. Huang, L.-M. Dong, G. S. Salvesen, M. Pericak-
Vance, D. Schmechel, A. M. Saunders, D. Goldgaber, and A. D. Roses, “Binding of human
apolipoprotein e to synthetic amyloid beta peptide: isoform-specific effects and implications
for late-onset alzheimer disease,” Proceedings of the National Academy of Sciences, vol. 90,
no. 17, pp. 8098–8102, 1993.
[118] J. Raber, D. Wong, G.-Q. Yu, M. Buttini, R. W. Mahley, R. E. Pitas, and L. Mucke,
“Alzheimer’s disease: Apolipoprotein e and cognitive performance,” Nature, vol. 404, no.
6776, p. 352, 2000.
[119] Y. Stern, S. Albert, M.-X. Tang, and W.-Y. Tsai, “Rate of memory decline in ad is related
to education and occupation: cognitive reserve?” Neurology, vol. 53, no. 9, pp. 1942–1942,
1999.
[120] J.-C. Lambert, C. A. Ibrahim-Verbaas, D. Harold, A. C. Naj, R. Sims, C. Bellenguez, G. Jun,
A. L. DeStefano, J. C. Bis, G. W. Beecham et al., “Meta-analysis of 74,046 individuals
identifies 11 new susceptibility loci for alzheimer’s disease,” Nature genetics, vol. 45, no. 12,
p. 1452, 2013.
[121] I. O. Korolev, L. L. Symonds, A. C. Bozoki, A. D. N. Initiative et al., “Predicting progression
from mild cognitive impairment to alzheimer’s dementia using clinical, mri, and plasma
biomarkers via probabilistic pattern classification,” PloS one, vol. 11, no. 2, p. e0138866,
2016.
[122] T. G. Beach, S. E. Monsell, L. E. Phillips, and W. Kukull, “Accuracy of the clinical diagnosis
of alzheimer disease at national institute on aging alzheimer disease centers, 2005–2010,”
Journal of neuropathology and experimental neurology, vol. 71, no. 4, pp. 266–273, 2012.
111
[123] National Institutes on Aging / National Institutes of Health, “Accelerating medicines
partnership - alzheimer’s disease (amp-ad),” 2019. [Online]. Available: https://www.nia.nih.
gov/research/amp-ad
[124] K. C. Arthur, A. Calvo, T. R. Price, J. T. Geiger, A. Chio, and B. J. Traynor, “Projected
increase in amyotrophic lateral sclerosis from 2015 to 2040,” Nature communications, vol. 7,
p. 12408, 2016.
[125] D. Hirtz, D. Thurman, K. Gwinn-Hardy, M. Mohamed, A. Chaudhuri, and R. Zalutsky, “How
common are the “common” neurologic disorders?” Neurology, vol. 68, no. 5, pp. 326–337,
2007.
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